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Crystallization is often a major bottleneck to macromolecular structure 
determination. This is particularly true for membrane proteins, which have hydrophobic 
surfaces that cannot readily form crystal contacts. Of the roughly 109,000 protein 
structures in the PDB, only about 539 represent unique membrane proteins, despite 
immense interest in membrane proteins from both a biological and therapeutic standpoint. 
Membrane protein crystallization has been facilitated by the development of new 
detergents, lipidic cubic phase methods, soluble protein chimeras, and non-covalent 
protein complexes. The design process of protein fusion constructs and non-covalent 
antibody fragments specific for each target membrane protein, however, is costly and 
time-consuming. An improved, more general method of membrane protein co-
crystallization is needed. This dissertation details the development of two approaches for 
cost-effective non-covalent crystallization chaperones: (1) Engineered hypercrystallizable 
Fab antibody fragment with high affinity for EYMPME (EE epitope), which form 
complexes with EE-tagged soluble and membrane proteins. (2) Engineered monomeric 
streptavidin (mSA2) for complexation with biotinylated membrane proteins. Both 
methods are generalizable through insertion of a short epitope into a surface-exposed 
loop of a membrane protein by site directed mutagenesis. Crystallization trials of 
representative chaperone-membrane protein complexes and possible difficulties with the 





CHAPTER 1: INTRODUCTION TO MEMBRANE 
PROTEIN CRYSTALLIZATION 
1.1 MEMBRANE PROTEINS AND THE IMPORTANCE OF DETERMINING THEIR 
HIGH RESOLUTION STRUCTURE 
1.1.1 The prevalence of membrane proteins in biology and pharmaceuticals 
Integral membrane proteins represent nearly 30% of all sequenced genomes (10), 
specifically, ~ 27% of the human genome (11). Membrane proteins and their 
corresponding functions are diverse, and include (a) receptors that mediate specific 
cellular responses upon ligand binding, (b) transporters and channels that control 
movement of substrates across membranes into the cell, (c) intramembrane enzymes that 
catalyze chemical reactions, (d) intramembrane structural and adhesion proteins that 
mediate cell-cell contacts and development of cell structure, and (e) intramembrane 
ligand proteins that enable communication between cells. Because of their broad 
functions and their location on the surface of the cell, membrane proteins represent over 
half of all known drug targets (11, 12). The study of membrane proteins is further 
motivated by the numerous associated diseases caused by mutations within membrane 
proteins. To name a few examples, a cause of early onset Alzheimer’s disease (AD) is 
mutations within presenilin (13), an intramembrane aspartyl protease that cleaves 
amyloid precursor protein to generate the amyloid β peptide that is deposited in the brain 
of AD patients. Mutations in the transporter cystic fibrosis transmembrane conductance 
regulator (CFTR) affect regulation of chloride ions and cause viscous secretions in the 




adrenergic receptor (β2AR), a G protein-coupled receptor (GPCR) are thought to be 
associated with certain asthma phenotypes (15).  
1.1.2 X-ray crystallography as a tool for studying proteins 
The three-dimensional (3D) structure of crystalline molecules, including 
macromolecules (DNA and proteins), can be determined by taking advantage of the 
diffraction of X-rays by the electrons in the highly ordered crystalline sample (16, 17). 
The resulting electron density map and best-fit model of the atoms in the protein 
molecule can lead to insights into the protein mechanism which may allow researchers to 
better understand associated diseases. The high resolution study of ligand-binding 
properties of the protein of interest can lead to drug discovery and structure-based drug 
design. An example of the value of crystal structures as a tool for drug design for a 
soluble protein can be seen in Chapter 6 of this thesis and a review of structural biology 
and drug discovery can be found in (18) and (19).  
1.1.3 Membrane protein structures are severely underrepresented  
Despite the importance and prevalence of membrane proteins throughout biology 
and human disease, their structures are severely underrepresented in the Protein Data 
Bank (PDB, www.rcsb.org). Of the 108,789 structures in the PDB as of May 13, 2015, 
only 539 structures are of unique membrane proteins (see 
http://blanco.biomol.uci.edu/mpstruc/). One of the first steps of protein X-ray 
crystallography is crystal growth, and challenges of membrane protein crystallization are 
numerous. Methods to overcome the challenges can be broken into 3 phases: molecular 
biology and expression, purification, and crystallization. Each phase has its own 




protein crystallization and the methods used in the following chapters, several emerging 
and successful strategies geared toward crystallization of membrane proteins are covered 
in the following sections. 
1.2 MOLECULAR BIOLOGY AND PROTEIN EXPRESSION 
During the molecular biology and expression phase of protein crystallography, 
endless modifications can be made to the protein construct and the expression protocol. 
Each new construct must then be tested for protein expression and often several, 
sometimes hundreds, of constructs are made and tested before successful crystallization. 
The following sections discuss some of the principles considered when designing 
constructs and expression protocols for protein crystallization, some of which are 
designed to increase protein crystallization propensity directly and some indirectly by 
increasing protein expression, stability, and/or solubility. Many of the following 
strategies have the disadvantage of solving the structure of a non-native protein, but the 
crystallization of the protein would likely otherwise be unsuccessful.  
1.2.1 Prokaryotic orthologs 
Though human membrane proteins may be of particular interest from a medical 
standpoint, they are especially difficult to express and crystallize. Eukaryotic proteins 
generally require chaperones and posttranslational modifications for proper folding, 
requiring the use of an expensive, time-consuming, and often low-yielding eukaryotic 
expression systems (20). Eukaryotic membrane proteins often have prokaryotic orthologs 
which can be expressed in higher yields in Escherichia coli and are easier to crystallize 
because eukaryotic proteins require posttranslational modifications and cofactors for 




significant insights into the human protein counterpart. Recent prokaryotic structures of 
important human proteins include vitamin C transporter from E. coli (21) glutamate 
transporter from archaeon Pyrococcus horikoshii (22), and the translocator protein from 
Rhodobacter sphaeroides (23). Though structures are likely very similar between the 
eukaryotic and prokaryotic orthologs, small differences in structure and function may 
limit drug discovery (24). 
1.2.2 Truncation or removal of regions by molecular biology 
Unstructured or flexible loop are difficult to crystallize because they lead to 
heterogeneity in the protein solution. Recently, Tanabe et al. (25) successfully 
crystallized human adiponectin receptors AdipoR1 and AdipoR2 by removing the N-
terminal 87 and 99 amino acids from AdipoR1 and AdipoR2 respectively. This truncation 
improved the expression and purification properties of the protein and allowed crystal 
growth, without changing its ligand binding properties (26). Similarly, the first 66 amino 
acids of the polymodal K2P channel TREK-1 were removed (27). This same principle is 
often employed by the cleavage of purification tags after affinity purification, which has 
been shown to increase crystal diffraction. A cleavage site must be inserted into the 
protein sequence in the molecular biology phase (see Chapter 2).  
1.2.3 Surface entropy reduction 
Surface entropy reduction (SER) is a method of systematically replacing small 
patches of 2 or 3 surface residues that have high conformational entropy (for example, 
lysine, glutamate, and glutamine) with residues of low conformational entropy. Alanine is 
a good replacement residue, and using threonine and tyrosine as replacement residues can 




of numerous soluble proteins (for example (29, 30), a list of structures solved using SER 
can be found at http://ginsberg.med.virginia.edu/Ser/), and the technique could be utilized 
in soluble loops of membrane proteins. If the protein structure is unknown, the 
determination of residues to mutate without disrupting structure and function can be 
difficult, but a prediction server is available (http://services.mbi.ucla.edu/SER/). The 
addition of nonpolar amino acids can decrease protein solubility and stability, making 
protein expression and purification difficult (31), therefore this method can only be 
utilized with proteins that are stable and relatively easy to express. 
1.2.4 Synthetic symmetrization 
To aid in crystallization, specific mutations are introduced on the protein surface 
to drive symmetric self-association of the target protein. For example, a single cysteine 
mutation was introduced on the surface of T4 lysozyme (T4L) to form an intermolecular 
disulfide bond, leading to several new crystal forms of T4L (32). The same approach was 
used to crystallize thrans CelA, a protein of previously unknown structure (33). A similar 
approach involves engineering metal-binding sites on the surface of the target protein to 
promote medal-mediated synthetic symmetrization (34). The utility of this method has 
been demonstrated using maltose binding protein (MBP) and T4L (34) and ferritin (with 
some variants forming 24-mers) (35), but to my knowledge, not membrane proteins. It 
may be difficult to design mutations for synthetic symmetrization for a protein of 
unknown structure, but principles of the design process have been discussed (34). 
1.2.5 Covalent crystallization chaperones  
Soluble, easily expressed, globular proteins have been fused to proteins that are 




soluble proteins have been used as so called covalent chaperones (or carrier proteins), 
including MBP (36-38), lysozyme (39), thioredoxin (TRX) (40). T4L (41-44) and 
apocytochrome b562RIL (BRIL) (45, 46) have been especially successful for the 
crystallization of GPCRs, by replacing the third intracellular loop (ICL3) or the N-
terminus with the covalent chaperone. This method has the further advantages that the 
covalent chaperone often increases protein expression level and solubility (47-50) and the 
fusion protein is often also used as a tag for affinity purification, streamlining the 
purification protocol (51, 52). A disadvantage of this approach is that the linker region 
between the covalent crystallization chaperone and the protein of interest is flexible and 
could introduce conformational heterogeneity in the crystallization drop (53). The 
addition of the covalent chaperone has also been shown to cause deformation in the 
structure of the target protein (54, 55). 
1.2.6 Stabilizing mutations and directed evolution  
Stabilizing mutations and directed evolution are techniques used to increase the 
protein expression, stability, and solubility, indirectly increasing the crystallization 
propensity of the protein. Stabilizing mutations are usually rationally designed point 
mutations. For example, seven non-conserved residues of a glutamate transporter were 
replaced with histidine residues which resulted in improved protein expression (22). 
Several other examples exist for the crystallization of membrane proteins (54, 56, 57).  
Directed evolution involves generating genetic diversity by error prone 
polymerase chain reaction (PCR), transforming the entire DNA library into the desired 
expression host, expressing the protein, then selecting for the desired property (58). The 




example, higher expression, increased activity, or higher melting temperature). For 
GPCRs, a protocol for directed evolution has been outlined by Schlinkmann and 
Plückthun (59, 60). For the selection process, the authors add a fluorescent ligand of the 
GPCR to the cells expressing the library of GPCR mutants. The cells are sorted using 
fluorescence-activated cell sorting (FACS), and cells with higher fluorescence will harbor 
GPCR DNA of protein capable of higher expression levels. The GPCR DNA is 
sequenced from single colonies and the protein expression and stability is analyzed. The 
successful mutant GPCR can be used for subsequent structural studies. For the GPCR 
neurotensin receptor 1 (NTR1) this method increased the expression over WT NTR1 by 
an order of magnitude (60).  
1.2.7 Expression platform 
The selection of an appropriate expression system is important for the adequate 
expression of membrane proteins, but remains largely empirical (61). Prokaryotic 
membrane proteins can often be recombinantly expressed in sufficient yields using E. 
coli expression systems. Eukaryotic membrane proteins, however, are more difficult to 
express due to required lipids, chaperones, and post-translational modifications (62), and 
often require the use of yeast (63-66), human embryonic kidney cells (HEK) (67-69), or 
insect cells (25, 27, 70, 71). Different expression systems must often be tested before a 
system that produces suitable protein yields is determined (72). Manipulation of the 
DNA, however, is often more fruitful than changing expression systems because it is 
time-consuming and expensive to set up and optimize new systems. 




Protein purification is the second major impediment to the crystallization of 
membrane proteins. The same optimizations done for the purification of soluble proteins 
must also be considered with membrane proteins and are not covered here.  
1.3.1 Detergent selection for membrane solubilization and purification 
Hundreds of detergents are commercially available, but the detergents used for 
membrane protein studies must retain both structure and function of the protein, and a 
suitable detergent is generally determined by trial and error. Further considerations must 
be made for detergents used in crystallography, as detergents undergo their own phase 
transition during the vapor diffusion process. Detergents also form micelles which, 
depending on micelle size, could encompass the few polar residues in the membrane 
protein that are available for forming crystal contacts. The detergents most successful for 
the crystallization of membrane proteins are N,N-dimethyldodecylamine-N-oxide 
(LDAO), n-octyl-β-D-glucopyranoside (OG), octyltetraoxyethylene (C8E4), n-decyl-β-
D-maltopyranoside (DM) and n-dodecyl-β-D-maltopyranoside (DDM) (73), but some 
proteins are unstable in the most popular detergents (73, 74). Each detergent must be 
screened for protein stability. One must also consider and monitor the amount of 
detergent in the sample, as excess detergent can lead to ligand dissociation and phase 
separation in the crystallization drop (75) (see Chapter 2). 
1.4 MEMBRANE PROTEIN CRYSTALLIZATION 
Even after the successful expression and purification of stable protein, 
crystallization can be quite difficult. The following sections outline some methods that 





1.4.1 Limited proteolysis 
Similar to the removal of disordered regions in the molecular biology phase, 
limited proteolysis removes disordered regions after protein purification. Cleavage trials 
with low levels of several proteases (e.g. trypsin, V8 protease, papain, thermolysin, and 
subtilisin (76)) are performed, and the samples are run on SDS-PAGE so the level of 
protein digestion can be analyzed. Once an appropriate protease and protease 
concentration are determined, the protease is added to the purified protein sample either 
prior to crystallization trials or within the crystallization drop. Disordered and flexible 
regions are then cleaved by the protease, allowing for the crystallization of core protein. 
Limited proteolysis was utilized to determine the core of UlaA, a vitamin C transporter 
(21). The full-length protein readily formed crystals, but the diffraction limit was about 
10 Å. In contrast, the truncated protein, which was missing 7 amino acids from the C-
terminus and the octahistidine tag, formed crystals that diffracted to 1.65 Å. Several other 
examples have been published (76-78).  
1.4.2 Lipid cubic phase (LCP) 
An alternative to the crystallization of membrane proteins in a vapor diffusion 
environment containing detergent is crystallization in the presence of a lipid bilayer 
system (24, 25). So called in meso crystallization employs a spontaneously formed cubic 
phase containing single lipid bilayers and aqueous channels that extend in three-
dimensions (79). The target protein is incorporated into the lipid phase, and 
crystallization cocktails are added. The protein molecules diffuse through the membrane, 




crystallized in lipidic cubic phase have been published (70, 80-83), and excellent reviews 
have been written on the theory and use of LCP (79, 84-86).  
1.4.3 Ligand or other binding partner 
Co-crystallization of a membrane protein with a known binding partner, for 
example a soluble protein or a high affinity small molecule ligand, can help stabilize the 
protein of interest and reduce conformational heterogeneity (24), which generally aid 
crystallization. Numerous membrane protein structures have been solved with a bound 
ligand (for example, (21, 87-91)). 
1.4.4 Non-covalent crystallization chaperones 
The category of non-covalent crystallization chaperones includes macromolecules 
used to aid in the crystallization of a difficult protein by increasing available hydrophilic 
area available for forming crystal contacts. In addition to the methods listed below, 
covalent crystallization chaperones are also in this category, but must be included at the 
gene level (see Section 1.2.5).  
1.4.4.1 Protein specific Fab, scFv, and nanobodies 
To increase the hydrophilic residues and surface area available for forming crystal 
contacts and possibly lock the protein into a specific conformation, antibody fragments 
are bound to membrane proteins, usually over size exclusion chromatography, prior to 
crystallization (24, 92). To generate antibody fragments specific for the protein of 
interest, hybridoma technology (93, 94) or phage display (95, 96) is used. This technique 
has had much success for the crystallization of membrane proteins using Fab fragments 
(97-101), single chain variable fragments (scFv) (101-103), and 13 kDa fragments 




crystallization chaperones. Though antibody fragment production has become somewhat 
routine, the procedure is still costly, labor-intensive, and time-consuming (24, 107, 108), 
and a new antibody fragment must be generated for each target protein.  
1.4.4.2 Ankyrin repeat proteins 
Directed evolution strategies were used by the Plückthun group to evolve 
Designed Ankyrin Repeat Proteins (DARPins) (109, 110). DARPins are made up of 
ankyrin repeats, a 33-amino acid sequence with secondary structure elements including β-
turn, two antiparallel α-helices, and a loop to link connecting repeats (111-113). The 
repeats form a crescent-shaped tertiary structure that binds a properly folded epitope 
(111-114). Similar to protein specific antibody fragments, a new DARPin is created for 
each target protein, which can be done using ribosome or phage display. The main 
advantage of DARPins over protein-specific antibody fragments are the expression levels 
that can be achieved in E. coli (>100 mg DARPin per liter of cell culture). DARPins have 
been generated for several membrane protein targets (109, 110), and their utility for 
crystallization has been shown using model membrane protein multidrug efflux pump 
subunit AcrB (115).  
1.4.4.3 Epitope specific antibody fragments 
Another type of non-covalent crystallization chaperone is an epitope-specific 
antibody fragment. A stable, easily expressed and crystallized antibody fragment that has 
affinity for a short epitope is generated and can then be used for complexation with any 
epitope-tagged protein. The epitope is introduced into the target protein easily using site-
directed mutagenesis (SDM). In contrast to protein-specific crystallization chaperones, 




To my knowledge, the only epitope-specific antibody fragment that has been successful 
in co-crystallization is a Fab fragment that recognizes a specific RNA motif (116, 117), 
though other attempts have been made. An anti-FLAG Fab fragment was made by 
truncating the Sigma anti-FLAG antibody and attempts of co-crystallization with a 
FLAG-tagged protein were unsuccessful (118). By our lab attempts of co-crystallization 
of the anti-EYMPME (EE) scFv (119), and the anti-EE Fab fragment ((120), see Chapter 
3) have also been unsuccessful. The addition of the epitope may cause unintended 
conformational heterogeneity, making the complex difficult to crystallize (see Chapter 4).  
1.4.4.4 Streptavidin as a crystallization chaperone 
The streptavidin-biotin interaction is one of the strongest non-covalent 




 M (121), but the 
tetrameric assembly of streptavidin makes it less attractive for use as a crystallization 
chaperone. A monomeric streptavidin has been engineered (6, 122), and could be of use 
as a crystallization chaperone for biotinylated membrane proteins (see Chapter 5). 
1.5 AN EXAMPLE: THE STRUCTURE OF HUMAN β2 ADRENERGIC 
RECEPTOR  
The Nobel Prize-winning (Brian Kobilka, Nobel Prize in Chemistry, 2012) 
structure of human β2AR coupled to a G protein (105) can be used as an impressive 
example of overcoming the challenges to the crystallization of membrane proteins. 
During the molecular biology and expression phase, the N-terminus of β2AR was 
truncated (see Section 1.2.2), and T4L was fused to increase solubility and crystallization 
propensity (see Section 1.2.5). Two surface methionine residues were replaced with 




to remove the glycosylation site (see Section 1.2.6). The protein was expressed in Sf9 
insect cells (see Section 1.2.7). For the protein purification phase, DDM was used for 
membrane solubilization and over 50 detergents were screened for the stabilization of the 
GPCR-G protein complex (see Section 1.3.1). For crystallization, a nanobody was 
generated to stabilize the GPCR-G protein interaction (see Section 1.4.4.1). A high-
affinity agonist, BI-167107, was added to the protein to restrict conformational 
heterogeneity (see Section 1.4.3), and the complex was crystallized in lipidic cubic phase 
(see Section 1.4.2). Figure 1 depicts some of the methods used. As shown by this 
example, it is sometimes necessary to use multiple techniques to obtain a high-resolution 
crystal structure of a difficult protein.  
 
1.6 THESIS OBJECTIVES 
 
Figure 1 The structure of β2AR complexed with its G protein as an example of 
techniques used to crystallize membrane proteins 
β2AR (green) was fused to T4L (purple) at the N-terminus. A nanobody (red) was used to 
stabilize the G protein (yellow-orange, cyan, and blue). A high-affinity ligand (yellow) was 





1.6.1 Development of an antibody fragment and monomeric streptavidin as 
crystallization chaperones for tagged membrane proteins.  
As noted extensively in this introduction, membrane proteins are difficult to 
crystallize and require special modifications and considerations. The objective of this 
work was to first prepare the membrane protein of interest, signal peptide peptidase 
(SPP), for crystallization by developing a protocol to express and purify SPP with 
adequate protein yield and stability (Chapter 2). The protocol encompasses the molecular 
biology used to construct the plasmid, protein expression, and purification. Detergents 
used for protein purification were screened using size exclusion chromatography and 
circular dichroism, and detergent concentration is measured using thin layer 
chromatography (TLC). 
The next objective was to generate an epitope-specific Fab antibody fragment for 
general use as a crystallization chaperone for membrane proteins (Chapter 3). Very few 
examples of epitope-specific crystallization chaperones exist, and the generation of a 
stable, easily expressed and crystallized anti-EE Fab fragment (Fab/EE) could aid in the 
rapid solution of membrane protein structures. This chapter details the process of 
generating the anti-EE Fab fragment, the expression, and purification. EE-tagged soluble 
proteins were used as test proteins to show that Fab/EE binds EE-tagged proteins by 
surface plasmon resonance (SPR) and size exclusion chromatography (SEC).  
Following the optimization of SPP and production of Fab/EE, the next objective 
was to obtain a co-crystal structure of SPP in complex with the Fab/EE crystallization 
chaperone (Chapter 4). Though I was ultimately unsuccessful with this objective, 




proteins was made. The ability of Fab/EE to form solution complexes with several EE-
tagged membrane proteins is shown. Molecular dynamic (MD) simulations were run 
which highlight the difficulties and drawbacks in the use of epitope-specific 
crystallization chaperones. Implications for the solution of membrane protein structures 
are discussed.  
A similar but unrelated objective to those above was to successfully use a 
monomeric version of streptavidin as a crystallization chaperone for enzymatically 
biotinylated proteins (Chapter 5). The test protein, MBP, was enzymatically biotinylated 
by biotin ligase (BirA) and a complex was formed with monomeric streptavidin over 
SEC. Though ultimately no co-crystal structure was produced, crystallization trials of the 
complex and lessons learned are discussed.  
1.6.2 Molecular basis of novel 1-deoxygalactonojirimycin arylthiourea 
pharmacological chaperones binding to α-galactosidase A for the treatment 
of Fabry disease 
Chapter 6 is unrelated to the previous chapters. The objective was to use X-ray 
crystallography to determine the orientation and hydrogen bonding interactions of 
designed pharmacological chaperones for the treatment of Fabry disease. The chapter 
details the design, synthesis, and testing of the novel chaperones. Current treatments for 
Fabry disease include enzyme replacement therapy to replace mutated α-galactosidase A 
(α-gal A) and the use of 1-deoxygalactonojirimycin (DGJ) as a pharmacological 
chaperone to stabilize the mutated protein and allow for trafficking to the lysosome. DGJ 
is largely hydrophilic, which limits the diffusion through the cell membrane. To increase 




substitutions to DGJ (DGJ-ArTs). The objective of Chapter 6 is to detail the design of 
DGJ-ArT pharmacological chaperones, test them in Fabry disease cells, and determine 






CHAPTER 2: EXPRESSION, PURIFICATION, AND 
DETERGENT OPTIMIZATION OF SIGNAL PEPTIDE 
PEPTIDASE: LESSONS FOR PREPARING MEMBRANE 
PROTEINS FOR STRUCTURAL CHARACTERIZATION 
2.1 INTRODUCTION 
As noted in Chapter 1, membrane protein structures lag far behind their soluble 
counterparts, in large part due to difficulty in protein expression (123). Mammalian 
membrane proteins often need to be expressed in eukaryotic expression systems because 
the proteins of interest require chaperones, specific lipids, and post translational 
modification for proper folding (123, 124). Eukaryotic expression systems are often 
costly, time consuming, and relatively low yielding (20). In contrast, bacterial expression 
systems require simple growth medium, have rapid cell growth, and can express 
membrane proteins in high abundance (20). This makes the archaeal (or bacterial, if 
available) orthologs much more attractive to pursue for structural studies, a strategy that 
has been met with considerable success (See (4, 125-127), for example). 
2.1.1 Biology of SPP 
SPP is an intramembrane aspartyl protease (IAP) with orthologs found in human to 
extremophilic archaea (128). All IAP family members have 9 transmembrane helices and 
share a conserved, membrane-embedded signature motif, YD in transmembrane helix 
(TM) 6 and GXGD in TM7, where X is any amino acid (129).  
In eukaryotes, following the cleavage of a the signal peptide of a nascent protein by 
signal peptidase, SPP uses two aspartate residues to cleave type-2 signal peptides from 
the endoplasmic reticulum (ER) membrane (Figure 2, (5)), and the remnant short 




Drosophilia (130), detoxified as shown by cleavage of the signal peptide of eosinophol 
cationic protein by human SPP in a human carcinoma cell line (131), or act as signaling 
molecules for cell-cell communication, as has been demonstrated for MHC class I (132) 
and HLA-E molecules (133, 134). Human SPP is also responsible for the processing of 
the N-terminal core domain of hepatitis C virus, a step required for efficient propagation 
of the virus (5).  
 
Presenilin, the protease mentioned in Chapter 1 for its role in Alzheimer’s disease, is 
similar to SPP in structure, with opposite topology. Presenilin and SPP are inhibited by 
some of the same active-site directed molecules, indicating that the active sites are similar 
(135). Unlike SPP, presenilin requires self-cleavage into two fragments and several 
cofactors for activity (136), making expression, purification, and crystallization of 
presenilin very difficult. Because of its role in the cleavage of diverse signal peptides, 
maturation of hepatitis C virus, and similarity to presenilin without some of the 
challenges, SPP is an attractive target for structural studies.  
 
Figure 2 Cleavage action of SPP in membrane of the ER 
After protein synthesis on the ribosome, the ER-targeting signal peptide of the nascent protein 
is cleaved by signal peptidase (1). The signal peptide remaining in the membrane is then 






2.1.2 Chapter Overview 
In this chapter, I present the protocol developed for orthologs of SPP, which is easily 
adapted for other α-helical membrane proteins. Orthologs of human SPP have similar 
inhibition profiles (135, 137-139) and cleavage patterns (135), all which strongly suggest 
these enzymes share a similar structure and utilize a common chemical mechanism. 
Unlike human SPP, archaeal SPPs are not glycosylated and are active after 
overexpression and purification in heterologous bacterial hosts, though their biological 
function is unknown (4, 140). Our approach to the expression and purification of SPP has 
been to express archaeal orthologs in E. coli using a pET vector encoding a C-terminal 
hexahistidine tag, isolate membrane, solubilize in DDM detergent, purify using nickel 
affinity chromatography, and further polish the sample purity using size exclusion 
chromatography. We then screen detergents for enhanced protein stability using circular 
dichroism because protein stability correlates with crystallizability (141), and proteins in 
stabilizing solutions maintain monodispersity longer (142). By optimizing such 
conditions, we allow for more time to perform activity assays and crystallization trials. 
We are also concerned with the amount of detergent in our final purified sample, as 
excess detergent can lead to ligand and subunit dissociation and phase separation in the 
crystallization drop (75). Here, we outline the work flow developed and optimized for our 
lab to determine ideal buffer conditions, detergents and their concentration for structural 
studies. Our methods were developed with relatively limited resources and thus can be, at 
best, considered medium-throughput. Wherever possible, notes for troubleshooting and 
alternative methods have been included in the discussion.  




Professor Raquel Lieberman optimized the original SPP purification protocol, 
including membrane solubilization and Ni
2+
-affinity chromatography. Sibel Kalyoncu 
and I cloned Methanoculleus marisnigri SPP from genomic DNA and optimized the 
purification protocol including membrane solubilization, Ni
2+
-affinity chromatography, 
and gel filtration. The design of the workflow to determine appropriate detergents and 
detergent concentrations was a collaborative effort between Dr. Lieberman, Sibel, and 
myself. All detergent screening by gel filtration and CD data were performed by either 
Sibel or me, as we split up the numerous constructs for testing. The TLC protocol was 
optimized by me, and Sibel used the TLC assay for testing several constructs to 
determine final detergent concentration.  
2.1.4 Publication resulting from this work 
 This protocol will be published as a chapter in Methods in Molecular Biology 
volume titled Heterologous Expression of Membrane Proteins: Methods and Protocols 
(143). 
2.2 METHODS/PROTOCOL 
2.2.1 Signal peptide peptidase ortholog selection 
The Domain Enhanced Lookup Time Accelerated (DELTA) feature of Basic 
Local Alignment Search Tool for proteins (BLASTp (144), http://blast.ncbi.nlm.nih.gov/) 
was used to identify prokaryotic SPPs by excluding eukaryotes (taxid: 2759).  
2.2.2 Molecular biology for signal peptide peptidase orthologs 
Haloarcula marismortui (H. mar), Halobacterium salinarum (H. sal), and 
Methanoculleus marisnigri (M. mar) genomes were purchased from ATCC 




SignalP 4.0 (146) were used to predict the presence of a signal sequence. The genes of 
the target proteins (Figure 3) with the addition of restriction sites NcoI and SalI were 
amplified by PCR and ligated into pET-22b(+) vector. To some constructs, a cleavage 
site for tobacco etch virus (TEV) protease (ENLYFQS) was inserted between the SPP 
gene and the hexahistidine tag using primers listed in Table 1. Gene sequence fidelity is 
confirmed by DNA sequencing (MWG Operon, www.operon.com). 
2.2.3 TEV protease expression and purification 
Though TEV protease can be purchased, we have found that it is quite easy to 
prepare it in-house. The S219V mutant TEV protease is expressed in E. coli as a MBP 
fusion with a TEV protease site in the linker region between the two proteins, and is 
purified as previously described (147). The protein is stored in phosphate buffered saline 
(PBS) at roughly 1.6 mg/mL at -80 °C until needed.  
2.2.4 Signal peptide peptidase expression 
After transformation into E. coli Rosetta 2(DE3), a single colony is added into a 
200 mL Luria-Burtani (LB) supplemented with 60 µg/mL ampicillin and 34 µg/mL 
chloramphenicol. The starter culture is incubated for 18-20 hours at 37 °C with shaking at 
225 RPM. The next day, 1 L LB containing 60 µg/mL ampicillin and 34 µg/mL 
chloramphenicol is inoculated with 10 mL of the starter culture. Cultures are incubated at 
37 °C and 225 RPM until optical density at 600 nm (OD600) reached 0.6-0.8, at which 
point the temperature is reduced to 18 °C and incubated for 1 hour before inducing 
protein expression by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside 




harvested by centrifugation at 2500 x g for 10 minutes before flash freezing in liquid 




Figure 3 Alignment of human SPP with 3 archaeal SPP orthologs 
Alignment was performed using Clustal Omega and rendered in ESPript (1). Identical residues 
in all four sequences are white with red background. Similar residues are in red and conserved 
patches are boxed in blue. The conserved motif of all IAP family members is in bold white, 
with the catalytic aspartate residues denoted with a red arrow. α-helices are marked by spiral 






Table 1 Primers used for the insertion of a TEV cleavage site in M. mar SPP 
 Forward primer Reverse Primer 
Insertion of TEV 




















2.2.5 Membrane isolation from harvested cells 
A 7-8 g mass of cell pellet is resuspended on ice in 25-30 mL cell lysis buffer (50 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 200 mM 
NaCl, Roche Complete ethylenediaminetetraacetic acid (EDTA) free protease inhibitor 
cocktail) and lysed by French press at 18,000 PSI cell pressure. Cellular debris is pelleted 
by centrifugation (5000 x g for 15 minutes) at 4 °C. The supernatant is placed in a new 
centrifuge tube and the centrifugation step is repeated until no discernible pellet 
remained. The supernatant from the prior step is combined and subjected to 
ultracentrifugation at 120,000 x g for 45 minutes at 4 °C to pellet membrane. Membrane 
is then placed in 7 mL Dounce homogenizer and resuspended in 7 mL cell lysis buffer 
(without protease inhibitor). Sample is subjected to ultracentrifugation again, and pellet is 
added to a microcentrifuge tube and flash frozen in liquid nitrogen for storage at -80 °C.  
2.2.6 Protein solubilization from membrane and purification by Ni2+-affinity 
chromatography 
Approximately 0.3 to 1 g of wet membrane is thawed and resuspended in 7 mL 
membrane resuspension buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 20 mM 
imidazole) in a 7 mL Dounce homogenizer. Separately, a 1% solution of DDM or fos-




make a 1% (w/v) solution of solubilized membrane; e.g. 1 g DDM is dissolved in 93 mL 
membrane resuspension buffer, and added on ice to 1 g wet membrane resuspended in 7 
mL buffer. The membrane solution is stirred at 4 °C for at least 1 hour. The sample is 
then centrifuged at 181,000 x g for 45 minutes at 4 °C to remove unsolubilized material. 
For purification, the solution is loaded into an appropriate superloop connected to an 
AKTA fast protein liquid chromatography (FPLC) instrument (GE Healthcare) or other 
similar automated purification instrument. The protein is purified by Ni
2+
-affinity 
chromatography using a 1 mL Ni
2+
-affinity column (GE Healthcare) equilibrated with 50 
mM HEPES pH 7.5, 500 mM NaCl, 20 mM imidazole, and 0.1% DDM (Buffer A) and 
eluted with an imidazole gradient by mixing with 50 mM HEPES pH 7.5, 500 mM NaCl, 
500 mM imidazole and 0.1% DDM (Buffer B). Peak elution fractions are pooled and 
concentrated in a 10K molecular weight cut-off (MWCO) Amicon Ultra centrifugal filter. 
Prior to SEC (see next section), and for constructs containing a cleavable 
hexahistidine tag, the tag is removed by incubation with TEV protease. The protein 
sample is exchanged into gel filtration buffer (50 mM HEPES pH 7.5, 200 mM NaCl, 
0.0174% DDM) before the addition of 1:1 TEV protease:SPP mass ratio. The TEV 
protease/SPP mixture is incubated at 4 °C for 16 to 20 hours to complete the cleavage 
reaction. The sample is repurified by Ni
2+
-affinity chromatography using the same 
buffers, this time collecting the flowthrough material; the elution fractions contain the 
uncleaved protein and TEV protease.  





An overview of our procedure for using gel filtration and circular dichroism (CD) 
to measure protein stability in different detergents is presented in Figure 4. Following 
Ni
2+
-affinity chromatography described above, the sample is divided into 6 aliquots of 
approximately 250 µL each for testing each of 6 different detergents. In turn, each sample 
is injected on a Superose 12 10/300 column equilibrated with 2 column volumes of gel 
filtration buffer supplemented with 2X the critical micelle concentration (CMC) of a 
selected detergent. In the examples presented here, FC12, DDM, DM, 5-cyclohexyl-1-
pentyl-β-D-maltoside (Cy-5), LDAO, 2,2-didecylpropane-1,3-bis-β-D-maltopyranoside 
or lauryl maltose neopentyl glycol (LMNG), were tested (see Figure 5 for structures of 
detergent molecules). Initial assessment of protein stability includes inspection of elution 
peak intensity and shape. Protein detergent complex (PDC) size is evaluated by retention 
volume and purity is assessed using unboiled samples on SDS-PAGE (148). 
 
2.2.8 Protein stability in different detergents by CD 
 
Figure 4 Workflow to determine protein stability in different detergents using circular 
dichroism.  





To assess protein thermal stability, peak elution fractions from each Superose 12 
purification are concentrated to 8 µM in 10K MWCO Amicon Ultra centrifugal filter. 
Concentration is measured using molecular weight (MW) and extinction coefficient 
calculated by ExPASy ProtParam (149), and absorbance measured using a Nanodrop 
2000. A CD thermal unfolding experiment is conducted on each sample using a JASCO 
CD spectropolarimeter and a CD cell of 0.1 cm in width. CD parameters used are as 
follows: sensitivity=standard, start wavelength=300 nm, end wavelength=200 nm, data 
pitch=1, scanning mode=continuous, scanning speed=500nm/min, response time=1 
second, bandwidth=1 nm, accumulation=10, temperature increment=2 °C. The 
temperature versus the normalized molar ellipticity at the minimum wavelength is plotted 
in GraphPad Prism to determine the melting temperature (Tm) for each sample using 
Boltzmann sigmoid equation.  
 
 
Figure 5 Structures of detergents used for SEC and CD experiments  






2.2.9 Detergent quantification by TLC 
An overview of our procedure for using TLC for detergent quantification is 
presented in Figure 6. Detergent standards in gel filtration buffer (0.25%, 0.5%, 1%, 2%, 
3% detergent of interest) are prepared. After SEC in a detergent of interest, 500 µL of the 
sample is concentrated in an Amicon Ultra centrifugal filter with one of four different 
MWCOs, 10K, 30K, 50K, 100K until each filter contains less than 50 µL. The filtrate of 
each filter is then placed in a new 10K MWCO Amicon Ultra centrifugal filter and 
centrifuged at 8,500 x g until less than 50 µL remains. The total volume and the 
concentration of each sample is measured using a nanodrop and the protein extinction 
coefficient calculated by ExPASy ProtParam (149). 
Detergent standards (5 µL), concentrated samples, and the concentrated filtrate are 
spotted on a silica 60 TLC plate approximately 1 inch from the bottom of the plate, and 
the plate is allowed to dry for at least 30 minutes. The plate is then placed in a TLC 
chamber containing 0.5 inch TLC solvent (63:35 chloroform:methanol) until the solvent 
has run at least halfway up the plate. The TLC plate is dried in open air for 5 minutes, 
then placed into a chamber containing iodine chips until detergent samples are readily 







2.3.1 Molecular biology for target membrane protein 
Figure 3 shows the final Clustal Omega (150) alignment between human SPP and 
our selected targets, SPP from archaeal H. mar, H. sal, and M. mar rendered in ESPript 
(1) with secondary structure information from the crystal structure of M. mar SPP (PDB 
ID 4HYC) (4).  
pET-22b(+) was chosen as the expression plasmid because it contains N-terminal 
pelB leader sequence and C-terminal hexahistidine tag. To ensure correct protein 
insertion into the membrane, the protein sequence was analyzed by signal sequence 
prediction software, Signal-3L (145) and SignalP 4.1 (146) (Figure 7). Signal-3L 
predicted that the first 23 amino acids of M. mar SPP are a signal sequence, but SignalP 
4.1 predicted that M. mar SPP contained no signal sequence. Both the truncated (missing 
the predicted signal sequence) and full length M. mar constructs were prepared in pET-
22b(+) vector using SalI and NcoI restrictions sites with a TEV cleavage site inserted 
between the protein and the hexahistidine tag (Figure 8).  
 
Figure 6 Workflow to determine optimal filter MWCO for concentrating protein 
samples 










Figure 7 Signal-3L and SignalP signal sequence prediction for M. mar SPP 
(a) Output from Signal-3L predicting that the first 27 amino acids (red) from M. mar SPP are 
a signal sequence. (b) Output from SignalP predicting the same protein sequence does not 












   
AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGA 
             







       MetLysTyrLeuLeuProThrAlaAlaAlaGlyLeuLeuLeuLeuAlaAlaGlnProAlaMetAlaMetAspIleGlyIleAsnSerAspProAsnSerSerSer 
       
Signal peptidase 
     
             Sal 
I 
   
His Tag 
      
GTCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAAC 
ValAspLysLeuAlaAlaAlaLeuGluHisHisHisHisHisHisEnd 
    
             
             
T7 terminator 
     
TAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG 
     
Figure 8 pET-22b(+) DNA and amino acid sequence in the area where the ortholog DNA is inserted.  
Areas of interest are marked. The red DNA and amino acid sequence were replaced with the target DNA. The orange amino acids were removed 









2.3.2 Membrane protein expression 
All SPP orthologs were successfully expressed in Rosetta 2(DE3) E. coli cells 
using a general expression protocol with reduced temperature and elongated time for 
protein induction and expression. Typical yield is 2.5 g wet cell mass per liter of LB 
culture. 
2.3.3 Membrane isolation and protein purification 
For all SPP orthologs, membrane was first isolated from harvested cells then 
solubilized using DDM or FC12 as described in Materials and Methods. SPP is one of the 
most abundant protein in the solubilized sample (Figure 9, lane 1). SPP is then purified 
using Ni
2+
-affinity chromatography (Figure 10). The protein of interest elutes with 100-
165 mM imidazole, but contains low levels of several impurities (Figure 9, lane 2). After 
removal of the hexahistidine tag with TEV protease, SPP is slightly smaller, as observed 
by SDS-PAGE (Figure 9, lane 3). When not doing the detergent screen, protein collected 
in the flowthrough of the Ni
2+
-affinity chromatography step after TEV cleavage is 
concentrated in a 10K MWCO Amicon Ultra Centrifugal filter and purified using SEC, 
with final purified protein being in DDM being ~90% pure (Figure 9, lane 4).  
2.3.4 Protein stability in different detergents 
SPP orthologs were subjected to size exclusion chromatography in different 
detergents to assess the effect of the detergent on protein homogeneity and characteristics 
of elution volume. For both H. sal and H. mar SPP, LMNG and LDAO gave elution 




highest intensity peak for both SPP orthologs. Conversely, the lowest intensity and 






 affinity chromatographs from purification of two SPP orthologs 
Chromatograms were obtained using Unicorn software of H. mar SPP (left) and M. mar SPP 
(right). Blue trace is absorbance at 280 nm and green trace is % Buffer B. 
 
 
Figure 9 SDS-PAGE of M. mar SPP samples during each purification step.  
Broad range molecular weight marker with band sizes is shown on the left. M. mar SPP is the 
prominent band just under 30 kDa in each lane. Lane 1 is the sample after membrane 
solubilization. Lane 2 is the protein sample after HisTrap purification. Lane 3 is the protein 
purified over HisTrap column a second time after TEV cleavage of the hexahistidine tag. Lane 
4 is the purified protein sample after size exclusion chromatography on the Superose 12 






2.3.5 Protein stability in different detergents by circular dichroism 
CD thermal unfolding experiments for samples in each detergent were acquired, 
revealing a range of protein thermal stabilities. For H. mar SPP, Tms range from 79.0° for 
LDAO to 55.6° for DM (Figure 12 and Table 2). The Tm roughly correlated with the 
peak intensity from SEC, with the exception of DDM, which was the lowest intensity 
peak but not the lowest Tm. SPP samples in LMNG and LDAO eluted in the void volume 
of the SEC (Figure 11), and also had the highest Tm (Table 2), perhaps due to a 
stabilized oligomeric state not seen with the other detergents. The micelle size of LDAO 
(17-21.5 kDa (151, 152)) is significantly smaller than that of DDM (72 kDa (152)), 
indicating that the decrease in retention volume for the sample with LDAO was not due 
to micelle size. Interestingly, the Tms for samples with DM and DDM, which are only 
different in structure by 2 carbon atoms (Figure 5), differ by ~5 °C. Two zwitterionic 
detergents were tested (FC12 and LDAO, Figure 5) and the Tms differ by 15 °C. Though 
 
Figure 11 Gel filtration chromatograms of SPP orthologs in 6 detergents 
H. sal SPP in 6 detergents (left) and H. mar SPP in 6 detergents (right). Detergent 
abbreviations are as follows. FC12: fos-choline-12, DDM: n-dodecyl β-D-maltoside, DM: 
decyl β-D-maltoside, Cy-5: 5-cyclohexyl-1-pentyl-β-D-maltoside, LDAO: N,N-
dimethyldodecylamine-N-oxide, LMNG: 2,2-didecylpropane-1,3-bis-β-D-maltopyranoside or 





DDM gave the lowest intensity peak on size exclusion chromatography and did not give 
the highest Tm, DDM was chosen for solubilization and crystallization of M. mar SPP 
because DDM is the most common detergent for membrane protein crystallography and 
SPP crystals grew in DDM (data not shown).  
 
Table 2 Melting temperatures for H. mar SPP in 6 detergents 










2.3.6 Detergent quantification  
TLC was performed to quantify the detergent levels in the SPP samples after 
purification. The amount of detergent present in the sample decreased with increasing 
 
Figure 12 Normalized CD thermal unfolding experiment of H. mar SPP in 6 detergents.  





Amicon Ultra centrifugal filter size. Because the micelle of DDM alone is about 72 kDa 
(152), the 10K MWCO filter likely concentrated all of the excess detergent while the 
100K MWCO filter allowed some detergent to pass through the filter. All protein and 
detergent concentration values are listed in Table 3. Though the gel filtration buffer 
contained 2X CMC (0.0174%) DDM, the calculated starting detergent concentration of 
the sample that was concentrated using the 10K MWCO centrifugal filter was 0.0275%, 
indicating that more detergent was present in the sample than we expected.  
 
 
Figure 13 Detergent quantification of SPP sample using TLC 
(a) TLC from detergent filter test of M. mar SPP in 20 mM HEPES pH 7.5, 200 mM NaCl, 
0.0174% DDM. (b) Standard curve prepared using mean density values from Photoshop for 
each standard DDM concentration. R
2





Table 3 Data table for TLC detergent test 
Filter MWCO 10K 30K 50K 100K 
Starting concentration (mg/mL) 0.054 0.054 0.054 0.054 
Volume after concentrating (µL) 26 17.5 14 9 
Concentration factor
a
  19.2 28.6 35.7 55.6 
Theoretical concentration (mg/mL)
b
 1.038 1.543 1.929 3.000 
Measured concentration (mg/mL)
c
 0.995 1.296 1.388 1.848 
Protein recovery (%)
d
 95.8 84.0 72.0 61.6 
Theoretical [detergent]
e 
(%) 0.335 0.497 0.621 0.967 
Actual [detergent]
f 
(%) 0.529 0.687 0.771 0.885 
Detergent recovery (%)
g
 1.58 1.38 1.24 0.92 




100.0 87.5 78.5 57.9 
a
 Concentration factor = 500 µL/(volume after concentrating) 
b
 Theoretical concentration = (Starting concentration)*(Concentration factor) 
c
 Measured concentration was measured using a nanodrop and the protein extinction coefficient calculated 
by ExPASy ProtParam (149). 
d
 Protein recovery = (Measured concentration)/(Theoretical concentration) 
e
 Theoretical detergent concentration = 0.0174*(Concentration factor) 
f
 Actual detergent concentration was estimated using TLC (Figure 13a) and the standard curve prepared 
using mean density calculation in Photoshop from DDM standards on TLC (Figure 13b) 
g
 Detergent recovery = (Theoretical detergent concentration)/(Actual detergent concentration) 
h
 It is assumed that the 10K filter concentrates all the detergent. Since Actual detergent concentration was 
larger than Theoretical detergent concentration in most cases, the starting detergent concentration 
was calculated using the Actual detergent concentration and the Concentration factor for the 10K 
filter. That detergent concentration (0.0275%) was used to calculate the Detergent recovery. 
2.4 DISCUSSION AND LESSONS LEARNED 
In this chapter, our procedure for the production of highly stable SPP orthologs 
for structural characterization has been outlined. We clone SPP orthologs into pET-
22b(+) vector, express SPP in E. coli, purify by Ni
2+
-affinity chromatography and gel 
filtration. E. coli was chosen as the expression organism due to our lab having previous 
experience with E. coli expression systems, low cost, and ease of production of proteins 
from lower organisms. We chose to study archaeal orthologs of human SPP so that 
protein could be easily produced in high quantities. Then protein stability in different 




filtration was used to exchange the detergent in the protein sample and peak intensity and 
shape were used as indicators of protein stability. Tms were measured by CD thermal 
unfolding experiment in 6 detergents. The melting temperature of the sample is important 
as protein stability is related to crystallization propensity (153). Detergent concentration 
in the sample is important because too much excess detergent has been shown to 
dissociate ligands and negatively impact crystallization propensity (75). 
We began this process with 10 SPP orthologs, and the three SPP orthologs 
described here have been successfully expressed and purified. The leaky pipeline 
reinforces the notion that the ability to express and purify membrane proteins in 
heterologous hosts is highly individualized. Starting with more targets gives a better 
chance of success in the pipeline. We also prepared the full length and truncated versions 
of H. mar and M. mar SPP. Both constructs of M. mar SPP were active, had similar 
expression levels, and extents of crystallizibility (data not shown). By contrast, the full 
length construct of H. mar SPP could not be expressed in reasonable quantity, likely due 
to the addition of the pelB leader sequence with a natural signal sequence, which caused 
incorrect membrane insertion. 
For protein expression, we use E. coli Rosetta 2(DE3) cells, which contains a 
plasmid to correct for codon usage differences between the ortholog organism and E. coli 
host; some proteins express well in BL21(DE3) and C43(DE3). Variables affecting 
protein expression are numerous, and include media, cell line, optical density at 
induction, induction temperature, and induction duration. For each new protein, small 
scale expression trials are first conducted to determine the best conditions for high 




topology), a new tactic to rapidly assess homolog expression yields is to utilize a 
membrane protein-green fluorescent protein (GFP) fusion by whole-cell and in-gel 
fluorescence (154, 155). Other procedures for optimizing the expression of membrane 
proteins have been published (123, 124, 156) and could be used to increase the 
throughput of the overall procedure. 
For membrane solubilization, several detergents have been tested. LDAO, OG, 
DM, DDM have been successful for the crystallization of membrane proteins (73) so they 
are a good starting point for optimizing the solubilization. We chose to start with DDM, 
as it the most popular detergent for membrane protein crystallization (157). FC12 was 
used for solubilization of H. mar SPP, as purification in DDM did not yield pure protein 
(not shown). FC12, however, has not been very successful in the crystallization of many 
membrane proteins (157). As shown by the gel filtration and CD thermal unfolding 
experiment of H. mar SPP in 6 detergents, protein in FC12 is still very stable, though all 
crystal trials of H. mar SPP were unsuccessful in our lab.  
Our procedure to determine stabilizing detergents for each construct is a bit 
cumbersome as each protein must be purified in different detergents and then a CD 
thermal unfolding experiment must be performed in each detergent. Several other 
methods have been developed that could increase the throughput. Fluorescent size 
exclusion chromatography (FSEC) can be used with a GFP-fused protein without the 
need to purify the fusion protein before testing (154, 155, 158). A fluorescence detector 
must be in line with the gel filtration column to use this method, but small amounts of 
fusion protein can be detected. If buried cysteines are present, effects of detergents and 




thermal unfolding assay using N-[4- (7-diethylamino-4-methyl-3-
coumarinyl)phenyl]maleimide (CPM), a dye that fluoresces upon reaction with a thiol 
(159-161). Denaturing SDS-PAGE and size exclusion high pressure liquid 
chromatography (SE-HPLC) has also been used to determine the effect of detergents, pH, 
additives, and lipids on the proportion of monomeric protein and can be used with 
minimal protein amounts (142, 162, 163). 
Other methods for determining detergent concentration have also been developed. 
Phenol/sulphuric acid assay works to determine the concentration of sugar based 
detergents. A molybdate assay can be used for detergents containing phosphate. Nuclear 
magnetic resonance (NMR) can be used to identify and determine the concentration of 
detergents, though it takes a large sample (520 µL) and proteins can interfere with the 
signal. Gas chromatography coupled with mass spectrometry (GC-MS) can be very 
sensitive (0.05-3 µg DDM). Overall though, TLC is very simple to perform in the lab, 
requires only small amount of sample (5 µL) and works for many different detergents. 
All methods are reviewed in Price and Jia, 2013 (164). 
With Ni
2+
-affinity chromatography, it is important to be aware of the possibility 
of copurification with E. coli membrane protein AcrB. Serendipitously, AcrB binds to the 
nickel resin, is too large to pass through concentration devices, remains through SEC, and 
is hypercrystallizable even at low levels not detected on SDS-PAGE. Several labs (165), 
including ours, have crystallized and solved the structure of AcrB instead of our intended 
membrane protein. It is best to be wary of crystals resembling AcrB (see Figure 14) and 
to search the PDB for unit cell dimensions of any membrane protein crystals obtained by 




AcrB. To remove copurification with AcrB, we have added a TEV cleavage site between 
the protein and the hexahistidine tag. After purifying SPPs over the Ni
2+
-affinity column, 
we remove the hexahistidine tag using TEV protease, which can be readily prepared in 
the laboratory in high yield (147) and is insensitive to the specialized detergents used for 
membrane protein solubilization and purification. The TEV itself contains a C-terminal 
histidine tag, so a second purification over the Ni
2+
-affinity column traps TEV, uncleaved 
SPP, the tags, and AcrB; cleaved SPP is collected in the flowthrough fractions.  
 
The buffer exchange, cleavage, and second Ni
2+
-affinity chromatography steps 
can also be problematic from the standpoint of detergent concentration, which could 
hinder crystallization and ligand binding (75). After the first Ni
2+
-affinity 
chromatography step, the protein is buffer exchanged, concentrating the detergent at least 
20 fold. The protein is then cleaved and repurified over Ni
2+
-affinity chromatography. 
Since the flowthrough is then collected, all of the detergent concentrated in the buffer 
exchange step passes through the column and is collected with the protein. It is then 
concentrated ~64 fold (16 mL flowthrough concentrated to 250 µL for injection onto 
Superose 12 column), and the empty detergent micelles and the protein elution peak 
 
Figure 14 AcrB crystals using visible and UV light 
Crystals were obtained using crystallization condition containing 20 mM sodium citrate pH 
5.6, 0.1 M NaCl, and 17% polyethylene glycol 3350. The crystals formed within 6 days at 
room temperature. Space group is R23 and cell dimensions (Å) are a=144 b=144 c=518.36 





overlap on the gel filtration column causing the final detergent in the purified sample to 
be much higher than expected (as shown in Figure 13 and Table 3). In our experiments, 
we observed co-elution of empty DDM micelles and M. mar SPP. To decrease the 
detergent levels, other gel filtration columns should be tested to separate the detergent 
peak from the protein peak and different detergents should also be tested because 
detergent micelle size and protein elution volume (Figure 11) can vary greatly. Another 
option to remove detergent is dialysis, but sample storage stability could limit the utility 
of this method. For SPP, the activity has been shown to decrease after a week at 4 °C 
(data not shown), and dialysis could take several weeks to remove a sufficient amount of 
excess detergent. Our purified M. mar SPP does form reproducible crystals, so the excess 
detergent does not completely block crystallization, but may affect reproducibility of 
crystals in terms of their diffraction limit. 
In this chapter, we have employed some of the principles discussed in Chapter 1 
to increase the crystallizability of our target membrane protein, SPP. As evident in 
Chapter 1, numerous modifications must sometimes be made to the protein of interest in 
order to obtain quality protein crystals. Numerous crystallization conditions must be 







CHAPTER 3: CHARACTERIZATION OF EPITOPE-
SPECIFIC FAB ANTIBODY FRAGMENT FOR USE AS A 
GENERAL CRYSTALLIZATION CHAPERONE 
3.1 INTRODUCTION 
As noted in Chapter 1, crystallization of a given target protein can be a difficult step 
in structure determination, and is especially notorious in the case of membrane proteins. 
Numerous strategies have emerged to enhance the crystallizability of difficult proteins. 
These include protein modification such as random mutagenesis, directed evolution, or 
strategic mutations to improve crystallization propensity (166-169), generation or 
discovery of ligands to stabilize a specific protein conformation (170, 171), protein 
symmetrization by cross-linking or engineered metal binding sites (172, 173), limited 
proteolysis to remove flexible regions (76), and surface entropy reduction (174), among 
others. Recent advances in the crystallization environment for membrane proteins in 
particular include LCP and lipid-mimicking detergents to stabilize membrane proteins in 
a native-like environment (175-178). These methods are reviewed in Chapter 1. 
For membrane proteins, the so-called crystallization chaperone approach has been 
particularly successful. The desirable biophysical properties of chaperones include 
increasing hydrophilic residues available for forming crystal contacts, thus improving the 
likelihood of obtaining well-ordered crystals of the chaperone-target membrane protein 
complex. Covalent chaperones have been utilized to crystallize several GPCRs, where 
ICL3 (44, 179, 180) or the N-terminus (46, 181) is replaced by T4L or BRIL and 
generated as a chimeric protein. Non-covalent chaperones include antibody fragments, 




camlid domains (nanobodies) (104, 187, 189), and DARPins (190, 191). All of these non-
covalent binding partners are target specific, namely, for each new protein of interest, a 
new chaperone must be sought. Previously, we proposed the use of peptide-specific 
antibody fragments as an alternative to protein-specific crystallization chaperones (24).  
3.1.1 3D5 scFv 
This project began with the observation that anti-his scFv 3D5 crystallized in a 
unit cell that did not use the complementarity determining regions (CDRs) in the crystal 
contacts, but instead the CDRs opened into a 70 Å wide channel that could possibly 
accommodate a membrane protein (Figure 15) (7). Despite the favorable crystal lattice, 
3D5 is not an ideal antibody fragment for a crystallization chaperone. The low 
(micromolar) affinity for C-terminal histidines is not ideal for crystallization because of 
the pH sensitive binding to histidines. Commercial sparse matrix screens contain a wide 
variety of pHs which would be incompatible with the 3D5:His-tagged protein complex. 
3D5 is also not very soluble in solution and after expression, only 50% of the protein was 
 
 
Figure 15 Anti-his scFv 3D5 crystal lattice 
3D5 was crystallized in space group P3221 with 2.7 Å resolution. Light chain is colored light 
purple, heavy chain is dark purple. CDRs are in yellow. The CDRs point in toward a wide 





in monomeric form (Table 4).  
3.1.2 Conversion of 3D5 scFv to anti-EE scFv 
The Maynard (University of Texas at Austin) and the Lieberman Labs sought to 
convert the chaperone affinity to anti-EE (EYMPME). The EE epitope is an attractive 
peptide for chaperone binding because of the chemical diversity within the epitope 
(hydrophilic glutamates, hydrophobic methionines, restrictive proline), and the 
availability of commercial antibodies against the epitope for testing purposes. Upon 
conversion using directed evolution and phage display, the anti-EE scFv (3D5/EE_48 or 
scFv/EE) has 85% amino acid identity and increased from 50% monomeric protein with 
3D5 to 81% monomeric protein with scFv/EE (Table 4).  
 
Table 4 Biophysical characteristics of 3D5 compared to scFv variants (192) 
Parameter 3D5 scFv/EE 
Expression level (mg/L culture) 3.1 2.1 
Solubility (mg/mL) 2.3 12.8 
Melting temperature ( °C) 46.5 ± 0.5 47.2 ± 0.3 
% AA identity 100 85 
% monomeric protein
a
 50 81 
Kd (nM), 14B7-His6 (χ
2
) 4700 (0.08) ND
b
 




 767 (0.03) 
a 
% monomer measured upon initial purification 
b
 ND, not detected 
 
 
Co-crystallization was attempted with scFv/EE and its variants, with no success 
(193, 194). To the best of our knowledge, the only successful example of a target 
independent non-covalent chaperone has involved the use of a Fab fragment that 




Co-crystallization with client membrane proteins has been attempted by others using Fab 
fragments generated from commercially-available FLAG-binding monoclonal antibodies 
(118), but without documented success to date. Analysis of deposited cocrystal structures 
of membrane proteins using crystallization chaperones in the PDB reveals that the 
majority rely on the Fab format (24). This observation could be due to the increased 
surface area available to Fab fragments to form crystal contacts, or the increased stability 
the constant domains provide (196), compared to scFvs.  
3.1.3 Chapter overview 
In this chapter, we report the generation of a Fab fragment with nanomolar 
affinity for the EE epitope (Fab/EE), along with detailed structural and biochemical 
characterization relevant to its potential use as a crystallization chaperone. This chapter is 
also a report of successful complex formation with soluble proteins containing EE 
peptides, including two EE-tagged maltose binding protein constructs and an scFv with 
the EE epitope inserted in the flexible linker region. The likelyhood of Fab/EE being a 
successful crystallization chaperone is discussed. 
3.1.4 Individual contributions to the work 
This work is a collaborative effort between the Lieberman Lab at Georgia Tech 
and the Maynard Lab at the University of Texas at Austin. Kevin Entzminger and 
Jeongmin Hyun of the Maynard Lab cloned Fab/EE and performed thermal stability 
measurements. Other biophysical characterization was conducted by several members of 
the Lieberman group. I did all crystallography-related work, including crystal growth, 
data collection, refining and analysis. I largely wrote the paper, with certain sections 




3.1.5 Publications resulting from this work 
This research was published in Acta Crystallographica Section D, volume 71 in 
2015 (120). 
3.2 METHODS 
3.2.1 Molecular biology, expression and purification of Fab/EE 
To convert our previously described 3D5/EE_48 scFv (scFv/EE) (193) to Fab 
format, the variable light and heavy chains were sequentially sub-cloned via PCR into the 
NcoI-NotI and NheI-HindIII restriction sites, respectively, of the pFab vector (courtesy of 
Dr. Georgiou, University of Texas at Austin) (197) resulting in the vector pFab-Fab/EE. 
The vector provides in-frame, N-terminal periplasmic leader sequences and C-terminal 
peptide tags, a decahistidine-tag on the light chain and a FLAG-tag on the heavy chain 
(Table 7 and Table 8). The fidelity of the construct was confirmed by DNA sequencing 
(University of Texas Austin core facility) using primers 
5’-GTGAGCGGATAACAATTTCACACAGG (forward) and 
5’-GAGAAGGAGATATACATATGAAGTCG (reverse). Fab/EE was expressed in E. 
coli BL21(DE3). 2 mL LB (Fisher) culture supplemented with 60 µg/mL ampicillin was 
inoculated with a single colony and incubated for ~4 hours at 37 °C with shaking at 225 
RPM. The starter culture was diluted 1:100 in 500 mL Terrific Broth (TB, Fisher) in a 2 
L baffled flask and grown overnight with shaking at 225 RPM and 25 °C. Cells were 
pelleted at 4200 x g for 10 minutes and 4 °C, then the cell pellet was resuspended in 500 
mL fresh TB in 2 L flask and incubated for 1 hour at 25 °C, 225 RPM before inducing 
expression with 1 mM IPTG (Calbiochem) for 4.5-5 hours. Cells were pelleted and flash 




directly. Fab/EE was purified as reported previously for scFv/EE (198). Briefly, cell 
pellet was resuspended in 10 mL resuspension buffer (0.1 M Tris pH 8.0, 0.75 M 
sucrose) per gram of cell pellet. Osmotic shock was carried out by adding 7.5 mL 1 mM 
EDTA and 2.5 mg lysozyme per gram of cell and rocking or stirring for 45 minutes to 1 
hour at 4 °C, then adding 1 mL 0.5 M MgCl2 per gram of cell and stirring for an 
additional 45 minutes to 1 hour. After centrifuging for 20 minutes at 47,800 x g, 
supernatant was subjected to Ni
2+
-affinity chromatography with wash buffer 20 mM Tris 
pH 8, 500 mM NaCl, 20 mM imidazole and elution buffer containing either 100 mM 
EDTA or 500 mM imidazole. Fab/EE was further purified by preparative size exclusion 
chromatography using a Superdex 75 16/600 column equilibrated with 50 mM HEPES 
pH 7.5, 150 mM NaCl (HBS, Figure 16) on an ÄKTA FPLC system (GE Healthcare).  
3.2.2 Biophysical characterization of Fab/EE 
For all proteins, protein purity and size were assessed by standard reducing and 
non-reducing 12% SDS-PAGE analysis (148) using Coomassie stain for visualization of 
all other proteins (Figure 16 inset) with protein concentrations determined by micro BCA 
assay (Pierce) or estimated by absorbance at 280 nm combined with calculated extinction 
coefficients based on amino acid composition using ProtParam (149). Fractions of 
monomeric Fab/EE were pooled for subsequent experiments. Fab/EE solubility was 
determined as described previously (193) by measuring the concentration of soluble 
protein remaining after concentration to ~20 mg/mL and a 4-day incubation at 4 °C. 
Fab/EE thermal stability was measured by thermal unfolding after mixing 20 µL of 200 
μM Fab/EE or HBS only control with Sypro Orange (1 μl of 1:1000 dilution; Molecular 
Probes) in a Real Time PCR instrument (Viia
TM




0.96 °C/min from 25 °C to 90 °C and analyzed with Viia
TM
7 software (Applied 
Biosystems). Analysis to determine the Tm, the midpoint of unfolding, was performed 
with Viia
TM
7 software.  
3.2.3 Protein crystallization, data collection, structure determination and 
refinement 
Fab/EE (6.5 mg/mL in HBS) was crystallized at room temperature by the sitting 
drop vapour diffusion method. Conditions were optimized based on Wizard I/II (Emerald 
Biosystems) solution G4 containing 20% polyethylene glycol (PEG) 8000, 100 mM MES 
pH 6.0, 200 mM calcium acetate. Crystals used for structure determination were grown 
from a reservoir solution containing 0.1 M HEPES (pH 7.5), 100 mM calcium acetate, 
20-26% (w/v) PEG 8000, and 3% 1-propanol. Crystals were harvested and cryocooled in 
the reservoir solution supplemented with 15% glycerol. Crystallographic data were 
collected at beamline 22-ID of the Southeast Regional Collaborative Access Team (SER-
CAT) of the Advanced Photon Source (APS), (Darien, Illinois). Data were indexed, 
integrated, and scaled in HKL-3000 (199). The structure was solved by molecular 
replacement with Phaser (200) using a polyalanine search model prepared in 
CHAINSAW (201) that derived from the Fab portion of PDB ID 3SOB (202). The model 
was iteratively rebuilt in Coot (203) and refined in Phenix (204). Ramachandran outliers 
were determined using RAMPAGE (205). Crystallographic statistics are presented in 








Beamline source APS 22-ID 
X-ray wavelength (Å) 1.0 
Resolution (Å) 32.97 - 2.04 (2.11 - 2.04) 
Space group P1 
Unit-cell parameters 
 
a, b, c (Å) 53.559 67.131 71.877 
α, β, γ (°) 71.3 78.1 85.31 
Total No. of reflections 226544 
No. of unique reflections 57696 (5221) 
Multiplicity 3.9 (3.9) 
Completeness (%) 97.71 (93.40) 
〈 I/σ(I)〉 14.66 (2.70) 
Rmerge (%) 8.4 
Refinement statistics 
 
Final Rcryst 0.1641  (0.2198) 
Final Rfree
a
 0.2078 (0.2680) 







Bonds (Å) 0.004 
Angles (°) 0.9 









Most favoured (%) 97.7 
Allowed (%) 2.2 
Outliers (%) 0.1 
a
Rfree is calculated for a randomly chosen 5% of reflections which were not used for 
structure refinement  
b
As calculated by RAMPAGE (205) 
 
3.2.4 Computational analysis of Fab/EE crystal contacts 
PDBe Protein Interfaces, Surfaces and Assemblies (PISA) (206) was used to rank 
and analyze crystal lattice contacts by surface area and energy, as well as catalog critical 
amino acids in crystal contacts based on their formation of hydrogen bond or salt bridge 




monomer, the top three interfaces were identified as major crystal contacts and used for 
further analysis.  
3.2.5 Molecular biology, expression and purification of soluble test proteins 
presenting the EE epitope 
All soluble test proteins used were described previously (193). The EE-tag was 
appended to the C-terminus of maltose binding protein (MBP-EE) or into a surface loop 
of MBP replacing residues 170-175 (MBP-KEE). MBP with only a C-terminal 
hexahistidine-tag was used as a negative control (MBP-His6). An scFv with the EE-tag 
inserted into the flexible linker region (scFv-EE1) was used as another EE-tagged test 
protein for BIAcore. These proteins were expressed and purified via C-terminal 
hexahistidine-tag as described for Fab/EE. 
3.2.6 Binding assays and complex formation 
3.2.6.1 Surface plasmon resonance (SPR) 
Kinetic binding assays were performed with a BIAcore 3000 (GE Healthcare) 
instrument using immobilized bovine serum albumin (BSA) or Fab/EE coupled to CM5 
chips via NHS-EDC chemistry to a level of ~1200 response units (RU) as bait for ligand 
proteins. Responses due to sample refractive index changes and non-specific binding 
were corrected using signal from a flow cell coupled with BSA. Purified MBP-KEE, 
MBP-EE, scFv-EE1 or control MBP-His6 were injected in a duplicate dilution series from 
2 to 0.125 μM at a flow rate of 50 μl/min to minimize mass transport effects in a HBS 
running buffer supplemented with 0.005% Tween-20. Surface regeneration was 




3.2.7 Size exclusion chromatography 
Fab/EE–client protein interactions were further evaluated by SEC fractionation on 
an ÄKTA FPLC system (GE Healthcare) at 4 °C. Equimolar amounts of Fab/EE and 
MBP-KEE were incubated 90 min, either together or separately, at room temperature 
prior to fractionation on a Superdex S200 column (GE Healthcare) equilibrated with 
HBS. Elution fractions for each peak were precipitated by trichloroacetic acid (TCA) 
(207) and analyzed with 12% reducing SDS-PAGE.  
3.3 RESULTS 
3.3.1 Fab/EE molecular biology, expression and purification 
Fab/EE was generated by sub-cloning the variable regions into the di-cistronic 
plasmid pFab for bacterial expression (197). Here, each variable region is appended with 
a cognate human constant domain such that both polypeptide chains (VL-CL and VH-CH1) 
are targeted to the periplasm for correct assembly and disulfide bond formation. After 
osmotic shock and purification (Figure 16), similar levels of total and monomeric 
Fab/EE protein were recovered as for scFv/EE (2.4 mg/L culture versus 2.1 mg/L culture; 
87% versus 81% monomeric, respectively; Table 6). Fab/EE thermal stability was 
significantly enhanced as compared to scFv/EE (Table 6).  
3.3.2 Fab/EE structural characterization 
Crystals of Fab/EE belong to space group P1and its 2.0 Å resolution structure was 
solved by molecular replacement. Most residues were successfully modelled into the 
electron density map. Exceptions include S128 to S134 on chain H, FLAG tag on the C-
terminal end of the heavy chains (chains H and A) linker residues between the C-terminal 




(Table 7 and  Table 8). The only Ramachandran outlier in Fab/EE structure is H222, part 
of the decahistidine-tag of chain B, and fits well into the electron density. Two nearly 
identical molecules are present in the asymmetric unit. Chains L and B (light chains) 
superimpose with a root mean squared deviation (RMSD) of 0.599 Å and chains A and H 
(heavy chains) with an RMSD of 0.976 Å, using secondary-structure matching (SSM) 
function within Coot (208) (Figure 17a). Fab/EE chains A and B (monomer AB) and 
scFv/EE chains A and B (PDB ID 3NN8) are also nearly identical, with an RMSD of 
0.708 Å between two light chains and 0.581 Å between two heavy chains. 
 
 
Figure 16 Fab/EE purification 
Purified from the E. coli periplasm by Ni
2+
-affinity followed by SEC, Fab/EE elutes from an 
analytical gel filtration column as a single peak at the expected elution volume. Inset, non-
reducing (NR) and reducing (R) SDS-PAGE gel of a fraction taken from the major peak 
predominantly shows a single dominant band with >95% purity ~50 kDa and 31 kDa for non-








Expression level (mg/L culture) 2.1 2.4 
Solubility (mg/mL) 12.8 9.4 
Melting temperature ( °C) 47.2 ± 0.3 59.8 ± 0.1 
% monomeric protein 81 87 
a
As reported in (193) 
 
Table 7 Fab/EE heavy chains (chain H and A) Kabat numbering and modelled residues 
Residues in white were modelled in both chains. Residues in light grey were not modelled in 
chain H. Residues in dark grey were not modelled in chains H or A. Variable and constant 



















































































































































VH HCDR1 VH 
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HCDR2 VH    
H I Y W D D D K R Y N P S L K S R A T L T V D K S S S T V Y L E L R S L T S E D S S V Y Y C A R 
   

























































































































































   
HCDR3 VH CH1    
R G G S S H Y Y A M D Y W G Q G T T V T V S S A S F K G P S V F P L A P S S K S T S G G T A A L 
   

















































































































































   
CH1    
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CH1 Hinge Linker FLAG-tag     
S S L G T Q T Y I C N V N H K P S N T K V D K K V E P K S C D K T H T G G G G D Y K D D D D K 






 Table 8 Fab/EE light chains (chain L and B) Kabat numbering and modelled residues 
Residues in white were modelled in both chains. Residues in light grey were not modelled in 
chain B. The residue in pale blue was not modelled in chain L. Residues in dark grey were not 


































































































































































FLAG VL LCDR1 VL 
D Y K D I V M T Q T P S S L P V S L G D Q A S I S C R S S Q S I V H S N G N T Y L E W Y L Q K P G Q S P K L L I Y 

















































































































































         
LCDR2 VL LCDR3                   
K V S N R F S G V P D R F S G S G S G T D F T L K I S R V E A E D L G I Y Y C F Q G S L V P P T 
         

















































































































































         
VL CL                   
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CL                   
V Q W K V D N A L Q S G N S Q E S V T E Q D S K D S T Y S L S S T L T L S K A D Y E K H K V Y A 
         










































































































                      
CL   Linker Decahistidine-tag                                             
C E V T H Q G L S S P V T K S F N R G E C G G G G H H H H H H H H H H 




The lattice of Fab/EE demonstrates the variety of crystal contacts available to aid 
in the crystallization of client proteins (Figure 17b-d). Overall, the crystal contacts of 
Fab/EE had larger interface surface areas than those of scFv/EE, with the largest interface 
of Fab/EE calculated to be 1109 Å2 (Table 9 ID2, Figure 17b). The only residue that 
participates in crystal contacts in both Fab/EE and scFv/EE crystals is K107 (Figure 17b, 
Table 9), and the two interfaces are not similar. The Fab/EE interface contains the 
variable domain of chain B in one Fab/EE molecule interacting with the constant domain 
of chain L in the second Fab/EE molecule and vice versa (Figure 17b and Figure 18). 
         
         
Figure 17 Structure of Fab/EE 
(a) Overlay of two Fab/EE molecules in the asymmetric unit. RMSD of the two heavy chains 
(chain A and H) is 0.976 Å and RMSD of the two light chains (chain B and L) is 0.599 Å. (b) 
Fab/EE crystal contact ID2. The interface is 1109 Å2 and includes 10 residues from chain L and 9 
residues from chain B (both light chains, interacting residues are modelled as sticks). (c) Crystal 
contact ID5. Interaction between modelled histidine-tag from chain L and CDR of chain H of a 
different molecule. Interacting residues are modelled as sticks. (d) Fab/EE showing extended 
crystal contact areas and lack of channel that could accommodate a membrane protein. Colors as 




The corresponding scFv/EE interface is between the variable domains of the light chain 
and the heavy chain. The next largest Fab/EE contact by surface area, ID3, has 
interactions between heavy chains of adjacent molecules (not shown), with less than half 
the interface area of ID2 (Table 9). Unexpectedly, a portion of the decahistidine-tag on 
the C-terminal of the light chain of Fab/EE forms hydrogen bonding and salt bridge 
interactions (ID5) with the CDRs from the heavy chain. This interaction is seen in both 
molecules in the asymmetric unit (Figure 17c and Figure 19a-b). Finally, the P1 lattice 
lacks solvent channels to accommodate a client EE-tagged protein (Figure 17d) and the 
CDRs are being used in the crystal contacts.  
 




























 ID2 465 
K57, R58, 
S65, T68 
- - - 
 
ID3 456 
P9, K19, S30, 
S32, D72, 
K73, S75, 
T77, Y79, S98 
- - - 
 
ID4 393 






Fab/EE ID2 1109 - 








ID3 517 Q1, S28, V71, - E150, K213 - 










H224 (His-tag)  
a






Figure 18 Interactions and final 2Fo-Fc electron density for crystal contact ID2 
(a) Electron density for residues involved in crystal contact, contoured to 1σ. (b) Interactions 
between light chain (chains L and B) residues in contact ID2 depicted as dashed lines, with 





3.3.3 Fab/EE forms stable complexes with soluble EE-tagged client proteins 
To assess EE binding properties of Fab/EE, we first examined interactions with 
soluble proteins presenting the EE peptide by SPR. Binding affinity in the nanomolar 
range was measured for Fab/EE binding to MBP containing a C-terminal (MBP-EE), or 
an internal (MBP-KEE) EE peptide, as well as to an scFv with the EE peptide inserted 
into the flexible linker region (scFv-EE1) (Table 10, Figure 20a-c). No significant 
affinity loss was observed upon conversion of the scFv format to Fab (767 nm for 
scFv/EE binding to MBP-EE (192) and 308 nM for Fab/EE binding to MBP-EE), as has 
 
Figure 19 Interactions and final 2Fo-Fc electron density for crystal contact ID5  
(a) Electron density for residues involved in crystal contact from chains A and B, contoured to 
1σ. (b) Interactions between the histidine-tag on the C-terminus of the light chain (chain B) and 
the CDR of the heavy chain of a symmetry related molecule (chain A). Interactions are depicted 




been observed previously (209-211). No binding was observed to the negative control, 
MBP-His6 (Figure 20d).  
 








) KD (nM) 
MBP-EE 3.39 ± 1.23 x 10
4
 9.22 ± 0.15 x 10
-3
 308 ± 117 
MBP-KEE 1.25 ± 0.30 x 10
4
 7.88 ± 0.91 x 10
-3
 612 ± 95 
scFv-EE1 2.95 ± 1.47 x 10
5
 5.56 ± 1.66 x 10
-2
 224 ± 160 
 
 
Figure 20 Complexation data for Fab/EE binding to soluble EE peptide-containing 
proteins 
 EE-peptide-containing soluble proteins were injected in duplicate for each concentration 
tested, and binding to immobilized Fab/EE was monitored by SPR. Both duplicates traces are 
shown and demonstrate Fab/EE binding to (a) MBP-EE (b) MBP-KEE, and (c) scFv-EE1. (d) 
No binding was observed for MBP-His6. (e) Equimolar amounts of MBP-KEE and Fab/EE 
were equilibrated at room temperature separately or together prior to separation by analytical 
gel filtration. The sample containing both proteins eluted as a single peak with shorter 
retention than either individual protein. (Inset) fractions from each major peak were analyzed 
by reducing SDS-PAGE. (inset lane 1) peak fraction from the putative complex peak. (inset 




Since SPR employs surface immobilization strategies that may not accurately 
reflect binding in solution or in a crystallization drop, we assessed complex stability by 
SEC. Notably, SEC is often used to isolate protein-protein complexes prior to co-
crystallization trials (118, 212). MBP-KEE was selected among the aforementioned client 
proteins for solution complexation with Fab/EE. A clear shift in elution volume 
corresponding to higher molecular mass was observed for the complex, and complexation 
was confirmed by SDS-PAGE (Figure 20d).  
3.4 DISCUSSION 
3.4.1 Fab/EE rationale, cloning, and biophysical properties 
Previously, we reported the successful engineering of both EE- and hexahistidine 
peptide-specific scFvs for potential use as crystallization chaperones (119, 192). 
Ultimately, the anti-EE scFv proved higher affinity and preferable over its anti-
hexahistidine counterpart likely due to its chemical diversity, insensitivity to pH 
especially near physiological conditions, and greater compatibility with a variety of 
peptide insert locations (terminal and internal). Here we sought to convert our EE-
specific scFv to Fab format, which represents the majority of crystallization chaperone 
proteins in solved structures deposited to the PDB, and because Fab molecules typically 
exhibit better biophysical properties such as enhanced thermal stability and well defined 
oligomeric states compared to the scFv platform (196). We also postulated that the larger 
size of a Fab (~50 kDa versus ~25 kDa) would provide additional epitopes to mediate 
crystal contacts, especially advantageous for larger client membrane proteins. The 




correlated with crystallization success rates (213), render Fab/EE more promising than 
the parent scFv/EE for use in large-scale co-crystallization trials. 
3.4.2 Fab/EE structural characterization  
As noted in Section 3.3.2, Fab/EE was crystallized in space group P1 with CDR 
residues involved in crystal contacts and small solvent channels that could not 
accommodate a client protein, unlike the crystal lattice of scFv 3D5. Nearly all residues 
in scFv/EE are also in Fab/EE, with the exception of the heavy-light chain linker region 
in scFv/EE (194). All residues that form crystal contacts in scFv/EE are also available in 
Fab/EE, meaning that Fab/EE has a variety of residues and interfaces that are available 
for forming crystal contacts. We do not consider the Fab/EE lattice a negative aspect of 
Fab/EE for use as a crystallization chaperone because upon binding to target protein, 
Fab/EE would likely utilize other residues that are available for forming crystal contacts.  
Interestingly, the hexahistidine tag forms a crystal contact with CDR regions of 
the heavy chain, the area of antigen binding. Negative control proteins for complexation 
studies by SPR, SEC, and ELISA data (not shown) has confirmed that Fab/EE does not 
have any detectable affinity for the hexahistidine tag, so the His-tag/HCDR interface is an 
artifact of crystallization.  
3.4.3 Fab/EE forms stable complexes with soluble EE-tagged client proteins 
As shown in Section 3.3.3, Fab/EE binds several EE-tagged soluble proteins using 
SPR and SEC. MBP-KEE has an internal EE-tag, MBP-EE has an EE-tag at the C-
terminus, and scFv-EE1 has the EE-tag inserted in the linker region of the scFv. The 
binding affinity of Fab/EE for the EE-tag and the diversity of EE-tag placement within 




crystallization chaperone. Since Fab/EE does crystallize alone, it will likely be necessary 
isolate the Fab/EE:EE-tagged client protein complex over SEC prior to setting up 
crystallization trials, though that approach does not always produce complex crystals 
either (118). The length of the loop containing the EE epitope may also be very 
important, as longer loops tend to be flexible. Disordered or flexible regions are difficult 
to crystallize.  
In conclusion, we have developed Fab/EE for use as a crystallization chaperone 
for the crystallization of EE-tagged proteins. In this chapter, we characterized the Fab/EE 
antibody fragment using biophysical means including crystallization. For complexation 
studies, we used SPR and SEC to show that Fab/EE binds tightly to soluble EE-tagged 
proteins. In further chapters, we expand this idea to EE-tagged membrane proteins and 






CHAPTER 4: PROGRESS TOWARD CO-
CRYSTALLIZATION WITH EPITOPE-SPECIFIC FAB 
ANTIBODY FRAGMENT AND TAGGED MEMBRANE 
PROTEINS 
4.1 INTRODUCTION 
Chapter 1 set the stage for the crystallization of membrane proteins by reviewing 
methods that are used to increase the likelihood that a membrane protein will crystallize, 
including covalent and non-covalent crystallization chaperones. In Chapter 2, our 
methods for the expression and purification of archaeal orthologs of SPP were discussed, 
including the determination of protein stability in different detergents, which is an 
important factor for crystallization. Chapter 3 showed the characterization of an epitope-
specific crystallization chaperone, Fab/EE, that could be used to aid in the crystallization 
of EE-tagged membrane proteins. Examples of complexation of Fab/EE with soluble EE-
tagged proteins were shown using SPR and SEC.  
Here in Chapter 4, progress toward using Fab/EE as a crystallization chaperone 
for EE-tagged membrane proteins is shown, taking all that we learned in Chapters 2 and 3 
and putting them together. The pathway taken towards crystallization of a Fab/EE:EE-
tagged membrane protein will be discussed. Complexation studies were done with two 
test proteins, human adenosine A2a G protein-coupled receptor (A2aR-GFP-EE) and β-
barrel membrane protein E. coli intimin (intimin-EE7 and intimin-EE8). The high 
resolution structures of A2aR and intimin are published(214), and intimin is easily 
expressed and purified, making it ideal for structure studies.  
We are interested in SPP (see Chapter 2) from a crystallization standpoint. The 




SPP with Fab/EE) predates the structure by several years, and the structure is relatively 
low resolution, in an inactive confirmation, and missing loops of interest. Solution 
complexation studies were done with Fab/EE and EE-tagged H. Mar SPP (HmSPP-EE) 
and EE-tagged M. mar SPP (MmSPP-EE2).  
After numerous crystallization trials, molecular dynamic simulations with wild 
type (WT) intimin, intimin-EE7 and intimin-EE8, and the Fab/EE:intimin-EE complexes 
reveal unexpected increase in flexibility when mutating native loop residues to the EE 
epitope, which is likely hindering crystallization of the complex. Implications of these 
findings for co-crystallization and future directions are discussed. 
4.1.1 Individual contributions to the work 
This work is highly collaborative between everyone in the SPP subgroup in the 
Lieberman Lab. Jeff Culver designed and made the HmSPP-EE construct. Sibel 
Kalyoncu and I worked together to generate most of the MmSPP constructs. Sibel made 
the initial MmSPP-EE constructs and all of the variants with the shortened TM6-TM7 
loop. Swe-Htet Naing made the D to A inactive mutants of MmSPP. I made the 
remainder of the constructs. All GPCR expression, purification, and SPR was done by 
Kevin Entzminger (Maynard Lab, University of Texas, Austin). The intimin-EE 
constructs were designed by undergrads Ivan Morales and David Heaner, under the 
supervision of Sibel and myself. All complexation SEC data was collected by me, and the 
molecular dynamic simulations were done by J.C. Gumbart (Georgia Tech).  
4.1.2 Publications resulting from this work 
The intimin constructs were used for scFv complexation (119) and Fab/EE 




detailing Fab/EE characterization (120), and some of the MmSPP constructs were used 
for an SPP enzyme assay performed by Swe (manuscript submitted). 
4.2 METHODS 
4.2.1 A2aR expression and purification 
The plasmid pITy-A2aR-GFP-His10 was generously provided by Dr. Anne 
Robinson (University of Tulane). An EE-tagged variant, pITy-A2aR-GFP-EE, was 
generated by insertion of the EE epitope after wild-type residue Lys 209 (numbering as in 
GenBank AAA83270) in the ICL3, flanked by GS residues to allow for peptide 
accessibility (Figure 21). This was accomplished by SDM using QuikChange 
mutagenesis kit (Stratagene). Colony PCR was used to screen for modified plasmids as 
described previously (215). Correct EE peptide insertion of the final plasmid was 
confirmed by DNA sequencing. All primers used are listed in Table 11. 
Table 11 Primers for A2aR-GFP-EE SDM, colony screening, and sequencing 























Plasmids pITy-A2aR-GFP and pITy-A2aR-GFP-EE were transformed into S. 
cerevisiae BJ5464 by electroporation, with individual yeast colonies screened for high 
expression by whole-cell GFP fluorescence and the highest-expressing clones were used 
for subsequent protein purification as described previously (216). Briefly, cell lysis was 
accomplished by vortexing and protein was purified by Ni
2+
-affinity chromatography 
using wash buffer 50 mM NaH2PO4, 300 mM NaCl, 10% glycerol, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 0.1% DDM, 0.1% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 0.02% cholesteryl 
hemisuccinate (CHS), pH 8.0 with protease inhibitors and the same buffer for elution 
with the addition of 500 mM imidazole. Ni
2+
-affinity chromatography was followed by 
SEC using a Superdex 200 16/60 (GE Healthcare) column equilibrated with GPCR buffer 
 
Figure 21 Design and purification of A2aR-GFP-EE 
(a) Collier de perles diagram of the A2aR transmembrane regions 5-6 (TM5-6) depicting the 
insertion location for the EE peptide (shaded) with flexible linker residues. Residues 
homologous to those forming the Fab epitope in the Fab:GPCR cocrystal structure of β2 
adrenergic receptor (PDB ID 2R4S) are shown using hatched circles. (b) SDS-PAGE gel with 
silver staining shows single band at the expected monomer size for A2aR-GFP-EE after 
purification by Ni
2+
-affinity and SEC. Western blot of the same fractions using commercial 
anti-EE antibody confirms the presence of the EE peptide. The lower band represents 




(10mM NaH2PO4, pH 7.0 with 0.1% DDM 0.1%, CHAPS, 0.02% CHS). Purified protein 
was analyzed by SDS-PAGE and Western blot using the primary anti-EE peptide Glu-
Glu monoclonal antibody (1:1000 dilution in blocking buffer; Covance) and incubation 
with horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody 
(ThermoFisher). Signal was developed with SuperSignal West Dura Extended Duration 
Substrate (Thermo Scientific), and the resulting image captured on X-ray film.  
4.2.2 SPR with Fab/EE and A2aR-GFP-EE 
GPCR variants were injected similarly to MBP-EE in Section 3.2.6.1 with the 
exceptions of using a single dilution series from the highest concentration available upon 
purification and running buffer composed of HBS with 0.1% DDM. The association rate 
constant (kon), dissociation rate constant (koff), and equilibrium dissociation constant (Kd; 
Kd = koff/kon) were calculated assuming a Langmuir 1:1 binding model with 
BIAevaluation software. Only data sets with 
2
 < 0.5 were used. GraphPad Prism 5 was 
used for graphical representation.  
4.2.3 ELISA of Fab/EE and A2aR-GFP-EE 
Fab/EE binding to A2aR-GFP-EE was also assessed by ELISA. High-binding 96-
well plates (Costar) were coated with 20 µg/mL Fab/EE overnight at 4 °C. After a 1 hour 
incubation with blocking buffer at room temperature, purified A2aR-GFP-EE or A2aR-
GFP proteins were serially diluted 2-fold in blocking buffer (PBS, 5% milk). This was 
followed by 1 hour incubation with rabbit anti-GFP (Invitrogen), followed by washing, 
and 1.5 hour incubation with goat anti-rabbit HRP (Sigma). After washing, 3,3',5,5'-
Tetramethylbenzidine (TMB) substrate (Vector Labs) was added, signal allowed to 




SpectraMax M5 microplate reader (Molecular Devices). Data points represent the 
average of at least two measurements, including error bars equal to one standard 
deviation. GraphPad Prism 5 was used to fit data to a three-parameter logistic model and 
for graphical representation. 
4.2.4 SPP molecular biology, expression and purification 
4.2.4.1 HmSPP molecular biology, expression, and purification 
Online secondary structure prediction servers (for example, Jpred 3 (217) and 
PSIPRED (218)) were used to predict loops available for the insertion of the EE epitope. 
EE-tagged H. mar SPP (HmSPP) were prepared using SDM, and plasmid fidelity was 
confirmed by sequencing (MWG Operon). 
Protein expression and membrane isolation was carried out as stated in Section 
2.2.5. Isolated membrane was solubilized by first thawing frozen membrane on ice, then 
adding 0.3-1 g membrane to Dounce homogenizer with enough 50 mM HEPES pH 7.5, 
500 mM NaCl, and 20 mM imidazole to make a 100 mg/mL membrane solution. 
Membrane was resuspended using the loose plunger then the tight plunger until 
homogeneous. In a separate container, FC12 equal to the mass of membrane was added to 
50 mM HEPES pH 7.5, 500 mM NaCl, and 20 mM imidazole to make a 100 mg/mL 
FC12 solution. The membrane solution was added to the detergent solution and rocked at 
4 °C for at least 1 hour. Sample was then centrifuged at 181,000 x g for 45 minutes at 4 
°C to remove any unsolubilized material. The supernatant was added to a superloop of 
appropriate size (GE Lifescience) and purified by Ni
2+
-affinity chromatography using 50 




buffer and 50 mM HEPES pH 7.5, 500 mM NaCl, 500 mM imidazole, and 0.1% FC12 as 
the elution buffer.  
4.2.4.2 MmSPP molecular biology to insert the EE epitope and build construct library 
Since the structure was not available at the time this project was planned, 
secondary structure prediction software was used to predict the start and end of the long 
loop between TM6 and TM7. The EE tag was mutated in three places in the loop between 
TM6 and TM7 (Figure 22).  
 
 After initial complexation trials and the publication of the MmSPP structure (4), 
new constructs were prepared to hopefully increase the likelihood of crystallization. The 
first 23 amino acids, originally thought to be a signal sequence, were added back to the 
truncated construct using restriction free (RF) cloning (219). 5 mutations that were 
outlined in Li et al were made to increase expression and monodispersity (D40N, E42S, 
A147E, V148P, A229V) (4). The long loop containing the EE epitope was also truncated 
by 4, 8, and 12 amino acids to limit its flexibility. As mentioned in Chapter 2, a TEV 
cleavage site was also added to the end of several constructs so that the flexible 
hexahistidine tag could be removed which increases purity by removing proteins that 
bind the Ni
2+
-affinity resin and decreases flexibility by removing the unstructured 
hexahistidine tag. Most of these mutations were made to the WT and the MmSPP-EE2 






Figure 22 Alignment of MmSPP-EE variants showing EE tag in three locations 
The alignment shows all residues from the beginning of TM6 (V148) to the end of TM7 (V233) of 
MmSPP-EE variants. Helices are marked by black bars at the top of the alignment and are taken 
from the published structure (4). The catalytic aspartate residues (D162 and D220) are highlighted 
yellow, and the EE epitopes are colored brown, blue, and green.  
Mm SPP-EE1 V L P V L V L L V L L A V Y D A I S V Y R T K H M I T L A E G V L E E Y M P M E V V V P K R A D Y S F R K E G L N I S E G E E R G A F V M G M G D L I M P S I L V A S S H V
Mm SPP-EE2 V L P V L V L L V L L A V Y D A I S V Y R T K H M I T L A E G V L E T K A P I M V V V P K R A E Y M P M E E G L N I S E G E E R G A F V M G M G D L I M P S I L V A S S H V





Table 12 MmSPP constructs 
All constructs are in pET-22b(+) and were constructed by SDM of WT plasmid, with the 
exception of the full length (FL) which was constructed using RF cloning. The WT plasmid 
contains no EE tag, and EE1, EE2, and EE3 are shown in Figure 22. FL constructs contain the 
first 23 amino acids (teal), and ΔN23 constructs are missing the first 23 amino acids. The 
catalytic aspartate residues were mutated to alanines to make inactive mutants (orange). The long 
loop between TM6 and TM7 was truncated by 4, 8, and 12 residues to limit the loop flexibility 
(pink). The 5 missense mutations used for the crystal structure were added (dark green). Finally, a 
TEV cleavage site was inserted between the protein and the hexahistidine tag (purple).  
 
WT/EE FL D162/D220 Loop length Missense Mut. TEV/NO TEV Construct name 
WT ΔN23 DD WT no no  
WT ΔN23 DD WT no yes  
WT Yes DD WT no no   WT MmSPP 
WT Yes DD WT no yes  
WT ΔN23 AA WT no no  
WT ΔN23 AD WT no no  
WT ΔN23 DA WT no no  
WT ΔN23 DD WT yes no  
WT ΔN23 DD WT yes yes  
WT yes DD WT yes no  
WT yes DD WT yes yes  
EE2 ΔN23 DD WT no no   MmSPP-EE2 
EE2 ΔN23 DD WT no yes  
EE2 yes DD WT no no  
EE2 yes DD WT no yes  
EE2 ΔN23 AA WT no no  
EE2 ΔN23 DA WT no no  
EE2 ΔN23 AD WT no no  
EE2 ΔN23 DD -4 no no  
EE2 ΔN23 DD -4 no yes  
EE2 ΔN23 DD -8 no no  
EE2 ΔN23 DD -8 no yes  
EE2 ΔN23 DD -12 no no  
EE2 ΔN23 DD -12 no yes  
EE2 yes DD -8 no yes   MmSPP-EE2S2 
EE2 yes DD -12 no yes   MmSPP-EE3S2 
EE2 ΔN23 DD WT yes no  
EE2 ΔN23 DD WT yes yes  
EE2 yes DD WT yes no  
EE2 yes DD WT yes yes  
EE1 ΔN23 DD WT no no  






Table 13 Primers used to make MmSPP constructs outlined in Table 12 
Primers for RF cloning were designed using RFcloning.com (219), and primers for SDM were 
designed using Agilent QuikChange Primer Design Program 
(https://www.genomics.agilent.com/primerDesignProgram.jsp) 
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4.2.4.3 MmSPP-EE expression and purification 
The expression and membrane isolation of MmSPP-EE variants is identical to that 
of HmSPP-EE. The purification is similar to that of MmSPP-EE variants with the 
following exceptions. DDM is used for membrane isolation in a 1% solution with a ratio 
of 1:10 DDM:cell mass. For example, if 0.8 g membrane was isolated from 10 g cells, 1 g 
of detergent was used for a total of 100 mL resuspended membrane in 50 mM HEPES pH 
7.5, 500 mM NaCl, 20 mM imidazole. For Ni
2+
-affinity chromatography, the wash buffer 
contained 50 mM HEPES pH 7.5, 500 mM NaCl, 20 mM imidazole, and 0.1% DDM and 
the elution buffer contained 50 mM HEPES pH 7.5, 500 mM NaCl, 500 mM imidazole, 
and 0.1% DDM. After Ni
2+
-affinity chromatography, the protein concentrated in a 10K 
MWCO Amicon Ultra centrifugal filter and was further purified over size exclusion 
chromatography on either a Sephacryl 300 16/60 or Superose 12 10/300 column (GE 
Lifescience) using SPP gel filtration buffer containing 0.05% DDM as the running buffer.  
4.2.5 Fab/EE complexation with SPP-EE variants over size exclusion 
chromatography 
Following size exclusion chromatography, SPP variant was concentrated in a 10K 
MWCO Amicon Ultra centrifugal filter to <250 µL and incubated in a 1:1 molar ratio 
with Fab/EE (in 20 mM HEPES pH 7.5, 250 mM NaCl) at 4 °C for 2 hours prior to 
injection onto the size exclusion column (Superose 12 10/300, Sephacryl 300 16/60, or 
Sephacryl 200 10/300). SPP gel filtration buffer was used as the running buffer, 
containing either 0.1% FC12 for HmSPP variants or 0.05% DDM for MmSPP variants. 




The plasmid for E. coli intimin (214) was generously provided by Dr. Susan 
Buchanan (NIH). The published structure (PDB ID 4E1S) was analyzed for the presence 
of extramembraneous loops where the EE tag could be inserted. The designed constructs 
are shown in Table 14 and the locations are depicted in Figure 23. Intimin-EE3, -EE4, -
EE7, and EE-8 were made by SDM and primers are listed in Table 15. Other intimin-EE 
variants were not made because of the expense of the primers due to necessary length or 
failed SDM. Intimin-EE variants were expressed and purified as previously described for 
wild type intimin (214). Intimin-EE7 and –EE8 showed similar yields to WT intimin 
(Figure 24) 
Table 14 Design for intimin-EE constructs 
Constructs were designed based on the location of extramembranous loops. The letter color 
matches that of  and the EE tag is highlighted in gray. Extra amino acids (4 alanine residues) 
inserted for intimin-EE8 are highlighted dark gray. Note: intimin naming differs from Johnson et 
al (120) where intimin-EE7 was named intimin-EE1 and intimin-EE8 was named intimin-EE2.  
 
 

















































        
WT Intimin R M S G W H 
  
E S Y N K K 
  
D Y D E R P A N 
Intimin-EE5 R E Y M P M 
  
E S Y N K K 
  
D Y D E R P A N 
Intimin-EE6 R M S G W H 
  
E E Y M P M 
  
E Y D E R P A N 
Intimin-EE7 R M S G W H 
  
E Y M P M E 
  
D Y D E R P A N 
Intimin-EE8 R M S G W H A A E Y M P M E A A D Y D E R P A N 
                         
                         
 
L5 Region (354-370)
       
       
360 
       
370 
     WT Intimin Y G D N V A L F N S D K L Q S N P 
       Intimin-EE4 Y G D N V A L F N S E Y M P M E P 
       
                         
                         
 
Periplasmic Alpha Helix Region (412-433) 
  
         
420 
       
430 
   WT Intimin D K S W S Q Q I E P Q Y V N E L R T L S G S 
  Intimin-EE1 D K S E Y M P M E P Q Y V N E L R T L S G S 
  Intimin-EE2 D K S W S Q Q I E P E Y M P M E R T L S G S 
  Intimin-EE3 D K S W S Q Q I E P Q Y V N E Y M P M E G S 





Table 15 Primers used to make intimin-EE3, -EE4, -EE7, and -EE8 using SDM 




































Figure 23 Intimin structure showing location of designed intimin-EE constructs 
Amino acids 309-328 (L4) are colored blue, 354-370 (L5) are colored red, and 412-433 






4.2.7 Complexation of Fab/EE with intimin-EE7, -EE8 
For complexation with intimin, Fab/EE in 50 mM Tris pH 7.5, 200 mM NaCl, 
0.01% sodium Azade was combined with WT intimin, intimin-EE7, or intimin-EE8 at a 
1:1 molar ratio, and incubated for 2 hours on ice before injection onto a Superose 12 
10/300 GL column equilibrated with 50 mM Tris pH 7.5, 200 mM NaCl, 0.01% sodium 
azide, 0.05% DDM. Elution fractions for each peak were concentrated by Amicon Ultra 
centrifugal filter (30K MWCO, Millipore) and analyzed with 12% reducing SDS-PAGE.  
4.2.8 Molecular dynamic (MD) simulations  
The structure of WT intimin (PDB ID 4E1S) was placed in a 140- n-
dodecylphosphocholine (DPC) micelle using CHARMM-GUI (214, 220). DPC 
molecules were then mutated to DDM using a modified topology based on the 
CHARMM force field. Mutations for intimin-EE7 and the additional alanine insertions 
for intimin-EE2 were made in silico using VMD (221) and minimized using NAMD 
(222). An 8-residue epitope was docked to Fab/EE using ClusPro2 (223). Equilibration of 
this bound state over 10 ns was found to be stable and thus was used to model the 
 
Figure 24WT intimin, intimin-EE7 and intimin-EE8 SDS-PAGE 
Three intimin variants (WT, -EE7 and –EE8) were purified by Ni
2+
-affinity and SEC. 






placement of the Fab/EE on both intimin-EE7 and intimin-EE8. The systems were then 
each solvated with water and ionized with 250 mM NaCl. The resulting systems 
contained approximately 172,000 atoms each. Restraints were applied for a short 
equilibration to ensure the epitope-containing loop had stabilized in the Fab/EE binding 
site. The resulting systems were then run using unrestrained MD for 50 ns for intimin-
EE7 and 170 ns for intimin-EE8. All simulations were run using NAMD. The 
CHARMM36 (224) force field was used throughout, along with the TIP3P water model 
(225). A 2-fs time step was used for all bonded and short-range interactions, with long-
range non-bonded electrostatics calculated every other time step using particle mesh 
Ewald (226). A uniform temperature of 310 K and pressure of 1 atm were maintained. 
4.3 RESULTS 
4.3.1 EE peptide insertion into the extracellular loop of membrane proteins  
To determine candidate locations for EE peptide insertion into A2aR, the 
repertoire of previously solved GPCR structures was analyzed, revealing that most 
previously solved GPCR structures involved modification of the flexible ICL3 (227), 
either by truncation or through the use of covalent (T4L or BRIL) (228) or non-covalent 
(Fab) (186) crystallization chaperones targeting ICL3 identified by hybridoma 
technology (229). Specifically, 10 of the 12 residues that form the Fab epitope in the 
complex structure with the β2 adrenergic receptor (186) are contiguous in primary 
sequence, suggesting that the EE peptide inserted into the homologous location in A2aR 
would be accessible by our Fab/EE. Thus, the EE peptide flanked by flexible linkers 
(sequence: GS-EYMPME-GS), was inserted into the N-terminal segment of ICL3 of an 




wild-type residues (Figure 21a) to generate A2aR-GFP-EE. A2aR-GFP and A2aR-GFP-
EE were expressed and purified from S. cerevisiae. Silver staining SDS-PAGE reveals 
predominantly monomer A2aR-GFP-EE and Western blot shows EE peptide 
incorporation into only A2aR-GFP-EE and not wild-type A2aR-GFP (Figure 21b). 
Available loops for the insertion of the EE epitope in the representative -barrel 
membrane protein, E. coli intimin, were determined based on the high resolution crystal 
structure (230). Intimin was engineered with an internal EE peptide in one of three 
locations, the L4 region (intimin-EE7), L5 region (intimin-EE4), or the periplasmic α-
helix (intimin-EE3) (Figure 23). Due to poor expression of intimin-EE3 and –EE4, 
further experiments were not conducted. An additional construct possessing an insertion 
of 2 alanine residues on either side of the EE peptide in intimin-EE7 was generated, 
analogous to A2aR, which we postulated would increase the accessibility of the EE 
peptide for better Fab/EE binding (Figure 23). Both intimin-EE7 and intimin-EE8 were 
expressed and purified in similar protein yields to WT intimin (Figure 24) (214).  
 Though the MmSPP structure was published in early 2013 (4), the designed EE 
tagged variants of SPP predate the structure and the placement of the EE tag in HmSPP 
and MmSPP and was chosen based on predicted loops. The loop between TM6 and TM7 
is very long, and we postulated that it would be accessible for Fab/EE binding and that 
the addition of Fab/EE would help stabilize the long loop. The EE tag was placed in three 
locations within the TM6-TM7 loop of MmSPP to test whether placement affected 
protein expression (Figure 22). Since expression was largely unaffected (data not 
shown), MmSPP-EE2 was chosen for complexation and crystallization experiments 




4.3.2 Fab/EE forms complexes with EE-tagged membrane proteins  
4.3.2.1 Model α-helical membrane protein A2aR 
The accessibility and specific binding of Fab/EE to the EE peptide as presented 
by the A2aR-GFP was limited to ELISA (Figure 25a) and SPR (Figure 25b-c) due to the 
low yields of purified protein. For both experiments Fab/EE binding was only detected 
for EE-tagged proteins. The calculated KD from SPR for A2aR-GFP-EE (Table 16) is 
higher than the KD for the soluble proteins MBP-EE, MBP-KEE and scFv-EE1 (Table 
10), likely due to the presence of detergent.  
 








) KD (nM) 
A2aR-GFP-EE 2.13 ± 1.60 x 10
5
 3.92 ± 1.96 x 10
-3
 32 ± 24 
 
4.3.2.2 Model β-barrel membrane protein intimin 
The ability of Fab/EE to form a solution complex with an EE-tagged β-barrel 
membrane protein was tested with the intimin constructs by SEC (Figure 26). The 
 
Figure 25 Fab/EE binding to EE-tagged A2aR-GFP 
(a) ELISA analysis of Fab/EE binding to A2aR-GFP. Purified A2aR-GFP proteins with or 
without the EE peptide insertion were added to ELISA wells coated with Fab/EE or blocked 
control wells. Captured protein was detected using an anti-GFP antibody. (b-c) SPR analysis 
of binding. GPCRs were injected in duplicate for each concentration tested and binding to 
immobilized Fab/EE was monitored by SPR. Average traces are shown and demonstrate 
concentration-dependent binding to A2aR-GFP-EE. No binding was observed for A2aR-GFP 





Fab/EE:WT intimin elution trace has two peaks, the first representing WT intimin, the 
second Fab/EE, as confirmed by SDS-PAGE (Figure 26 inset, top). By contrast, when 
intimin-EE7 or –EE8 is mixed with Fab/EE, the species coelute. The first peak in the 
SEC trace has a shorter retention time indicative of a higher molecular mass complex 
expected for Fab/EE:intimin-EE complexes, concomitant with a reduction in the peak 
corresponding to Fab/EE alone (Figure 26 inset, middle and bottom).  
 
4.3.2.3 Α-helical membrane proteins HmSPP and MmSPP 
As further indication that Fab/EE complexes EE-tagged membrane proteins and 
as a step towards the crystallization of the Fab/EE:SPP-EE complex, the solution binding 
of Fab/EE to HmSPP-EE (Figure 27) and MmSPP-EE2 (data not shown) was also 
studied using SEC. Little to no coelution was detected with WT HmSPP and Fab/EE 
(orange). Fab/EE elutes in the first peak with HmSPP-EE (green), indicating that the two 
are binding over SEC. Similar results were obtained for MmSPP-EE2. 
 
Figure 26 Elution profile of purified Fab/EE incubated with intimin WT, intimin-EE7 or 
intimin-EE8 
Reducing SDS-PAGE analysis (inset) of fractions selected from 10.5 mL to 13 mL elution 






4.3.3 MD simulations of Fab/EE-intimin-EE complexes 
We postulated that upon binding of Fab/EE to intimin-EE7, intimin-EE8, HmSPP-
EE and MmSPP-EE2, loop residues would be immobilized and a stable complex for 
crystallization would be generated. Nearly 8000 crystallization trials of Fab/EE and EE-
tagged membrane proteins have been set up (~35 x 96 conditions from commercial 
screens and 29 x 24 conditions from homemade screens for intimin-EE, and 36 x 96 
conditions from commercial screens and 10 x 24 conditions from homemade screens for 
SPP-EE), with varying temperatures, concentrations, method (vapour diffusion with 
detergent (DDM), vapour diffusion with bicelle (3-([3-
Cholamidopropyl]dimethylammonio)-2-hydroxy-1-propanesulfonate (CHAPSO) and 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) mixture), or lipidic cubic phase 
(monoolein), data not shown). Both direct mixing of 1:1 Fab/EE : membrane protein-EE 
variant immediately prior to setting up trays and using the complex isolated from SEC as 
 
Figure 27 Fab/EE complexes with HmSPP-EE over SEC 
SEC was done on a sephacryl 300 16/60 column with Fab/EE and either WT HmSPP (orange) 
or HmSPP-EE (green). The elution volume of each fraction is listed at the top of the SDS-





above, were attempted. Unfortunately, none yet has resulted in diffracting crystals of 
Fab/EE:intimin-EE or any Fab/EE:SPP-EE complex (data not shown). 
To gain insight into why co-crystallization trials have not been successful in spite 
of demonstrated favorable solution properties, we turned to molecular dynamics. Since 
the structure of MmSPP is low resolution and missing the loop where the EE tag was 
inserted, MD studies were done on the Fab/EE:intimin-EE complexes. WT intimin, 
intimin-EE7, and intimin-EE8 were first modeled and allowed to equilibrate over 50 ns 
(Figure 28a). In comparison to WT intimin, intimin-EE7 and intimin-EE8 exhibit 
increased flexibility in residues 315-320, where the WT residues were mutated to the EE-
tag. Notably, the insertion of 2 alanine residues on each side of the EE-tag in intimin-EE8 
did not seem to cause a further increase in flexibility compared to intimin-EE7. After 
modeling the Fab/EE:intimin-EE interaction, the complex of Fab/EE:intimin-EE7 was 
equilibrated for 50 ns and Fab/EE:intimin-EE8 complex for 170 ns. The RMSF of 
residues 300-340 after 50 ns with and without Fab/EE bound (Figure 28b) indicate 
Fab/EE binding to both intimin-EE7 and intimin-EE8 slightly increases the flexibility of 
residues 312-325. Over the 170 ns simulation for the Fab/EE:intimin-EE8 complex, the 
position of Fab/EE in relation to intimin-EE8 is dynamic (Figure 28c-d). Such flexibility 
is likely due to mutations in the L4 loop in the membrane protein (Figure 29a). In 
particular, S316 of WT intimin forms hydrogen bonding interactions in both the WT 
intimin and the structure after 50 ns of MD simulations (Figure 29b). This interaction 
was broken when S316 was mutated to tyrosine within EYMPME of intimin-EE7, 
resulting in drastic changes within the loop (Figure 29c). The corresponding residue in 




resembles that of WT intimin but with E315 of intimin-EE8 in a similar position as the 
WT intimin residue S316 (Figure 29d). 
 
 
Figure 28 Molecular dynamics analysis of intimin-EE1 and intimin-EE2 with and 
without Fab/EE 
(a) Root mean squared fluctuation (RMSF) of residues 200-450 for intimin WT, intimin-EE7, 
and intimin-EE8 over 50 ns simulation. (b) RMSF of residues 300-340 for intimin WT, 
intimin-EE7, intimin-EE8 alone and in modelled complex with Fab/EE over 50 ns simulation. 
(c) Fab/EE:intimin-EE8 proposed complex structure at different time points during the 
simulation, colored from blue to red. Intimin-EE8 is shown as a cartoon and Fab/EE as ribbon. 
(d) A zoomed view of the intimin-EE8 loop containing the EE peptide during the same 







4.3.4 Fab/EE forms a solution complex with SPP constructs with truncated TM6-
TM7 loop 
Because the MD studies indicated that the insertion of the EE tag into a long 
soluble loop is likely detrimental to crystallization of the complex due to loop flexibility, 
MmSPP constructs with a shortened TM6-TM7 loop were made using SDM by deleting 4 
residues at a time. Because the deleted residues are near the EE tag, we were uncertain if 
 
Figure 29 Analysis of intimin L4 interactions 
(a) L4 loops of 4 intimin structures: WT intimin (PDB ID 4E1S), and WT intimin, intimin-
EE7 and intimin-EE8 after 50 ns simulation. (b) L4 loop of WT intimin from the PDB 
structure and WT intimin after 50 ns simulation. S316 is hydrogen bonding to E324 in 4E1S, 
and interaction is unchanged after 50 ns simulation. (c) WT intimin and intimin-EE7 after 50 
ns equilibration showing L4 loop residue 316 and E324 for each structure. (d) WT intimin and 
intimin-EE8 after 50 ns equilibration showing L4 loop residues S316 and E324 of WT 





the complexation over SEC would be successful. The SEC of Fab/EE and WT MmSPP 
resulted in 4 peaks (Figure 30, blue). The first small peak (labeled 1) was too low in 
concentration to be visible on SDS-PAGE. The second peak (labeled 3) contained only 
WT MmSPP. The third and fourth peaks, (labeled 4 and 5) contained 2 different species 
of Fab/EE. Both of the SECs with the shortened EE tagged variants contained 3 peaks 
(Figure 30, red and yellow). In each case, the first small peak contained some form of 
aggregated MmSPP-EE2S (2 or 3). The second peak (labeled 2) contained the 
Fab/EE:MmSPP-EE2S (2 or 3) complex. The third peak (labeled 4) contained 





Figure 30 Fab/EE complexes with MmSPP-EE2S constructs 
The complexation of Fab/EE with WT MmSPP (blue), MmSPP-EE2S2 (red), and MmSPP-
EE2S3 (yellow) was done using SEC on a superose 12 10/300 column. The same fractions 
from each SEC were run on SDS-PAGE and the fraction locations are marked with black 
lines. Fab/EE and MmSPP samples prior to complexation were also run on SDS-PAGE on the 





Crystallization trials of the Fab/EE:MmSPP-EE2S3 complex as isolated over SEC 
have been done (8 x 96 conditions from commercial screens). Only a single well 
contained 2 rod shaped crystals (~25 x 5 µm in size, grown in 0.2 M ammonium sulphate, 
14 % PEG 4000, 0.1 M CHES pH 10, 5.94 mg/mL complex, 20  °C for 23 days), but the 
crystals dissolved after being under the microscope for a brief period of time, and were 
not reproducible. 
4.4 DISCUSSION 
4.4.1 Conclusions: implications for chaperone-mediated crystallization of MPs  
Our engineered Fab/EE exhibits numerous favorable characteristics for use as a 
crystallization chaperone for difficult targets. Introduction of the EE epitope within 
membrane proteins is straightforward by site directed mutagenesis, leading to readily 
detected high affinity solution complexes. However, even when placement of the EE 
epitope does not interfere with protein expression and purification, an unintended 
consequence may be the removal of native contacts and thus an increase in 
conformational heterogeneity that is detrimental to crystallographic efforts. Such 
conformational changes can be challenging to predict, even for test proteins whose 
structures are known, and would be especially enigmatic in the case of target proteins of 
unknown structure. If a less flexible region of the target protein is not known, a reduction 
in loop flexibility is likely achievable by shortening the EE epitope-containing loop to a 
minimum number of residues that can still be complexed with Fab/EE. As shown in 
Figure 30, this is an ongoing project in the lab and will likely take time to determine the 




constructs. This approach may be successful in combination with other methods that were 





CHAPTER 5: MONOMERIC STREPTAVIDIN AS A 
CRYSTALLIZATION CHAPERONE FOR A 
BIOTINYLATED SOLUBLE TEST PROTEIN 
5.1 INTRODUCTION 
Streptavidin is a ~15 kDa protein from the bacterium Streptomyces avidinii (231) 
that forms a homotetramer to bind up to 4 molecules of D-biotin with unusually high 
affinity (KD=10
-14
 M) (232). The crystallographic structure of streptavidin was solved in 
1989 in the apo and biotin-bound forms (Figure 31) (233).  
 
  
Figure 31 Structure of WT streptavidin 
(a) The tetrameric structure of streptavidin is represented as four monomers in different colors 
with secondary structure shown as cartoon (PDB ID 1MK5 (8)). The bound biotin is shown as 
van der Waal’s spheres and surface representation is transparent grey. (b) The ligand binding 
cavity is shown as grey mesh and sidechains of residues within 4 Å are shown as sticks. 
Carbon atoms of the bound biotin are shown in cyan. W120 is colored in yellow, and is part of 






 The streptavidin-biotin complex has been used in a range of biological 
applications including ELISA, immunohistochemistry, cell-surface labeling, affinity 
purification, and FACS (9) because the complex is strong with rapid binding and 
resistance to extremes in pH, temperature, and denaturating agents (234). Tetravalent 
streptavidin, however, has drawbacks. The binding of multiple biotinylated ligands can 
cause aggregation of the target protein, which could alter the biological function and 
cause artifacts. For example, when used for labeling cell surface receptors, streptavidin 
can cause artificial crosslinking, which alters cellular signaling and induces receptor 
internalization (6). Germane to this thesis, as a crystallization chaperone, tetravalent 
streptavidin could induce protein aggregation or sample heterogeneity.  
 To address the issue of multivalency of streptavidin, three approaches have been 
taken. The first is to reduce the number of biotin binding sites within the tetramer. A 
heterotetramer containing two biotin-binding and two non-binding W120A mutant 
subunits was prepared by mixing mutant and WT streptavidin before in vitro refolding 
(235). Similarly, a monovalent streptavidin has been made with three non-binding mutant 
and one WT subunit (236). The monovalent straptavidin has femtomolar affinity for 
biotin the single biotin binding site, but the preparation process is cumbersome and the 
tetrameric protein is large which can prevent binding to partially buried biotin sites. The 
second approach to engineer a non-tetravalent streptavidin is by constructing a single-
chain version of the tetramer so that each biotin binding site can be engineered separately 
on one plasmid using molecular biology. The topology of the subunits was modified so 




were connected by a short linker region (9, 237). Again, the large size of the tetrameric 
protein could be detrimental to some labeling studies.  
 An third approach to obtain monovalent streptavidin is to engineer a stable 
monomer. Most of the reported monomers are unstable, prone to aggregation, and exhibit 
low affinity for biotin (238-240). Some have concluded that the loss of biotin affinity was 
due to the absence of the hydrophobic lid from adjacent subunits (Figure 31) (241, 242), 
but a dimeric version engineered by the Park lab at State University of New York 
(SUNY) Buffalo indicates that something else is responsible for the high biotin affinity 
(122). The dimer consists of two covalently linked subunits and contains the same 
binding site residues as the tetramer, but the affinity for biotin is 17 nM. This suggests 
that tetramerization is not the only parameter that causes the high affinity for biotin. To 
engineer a monomeric streptavidin, the Park lab introduced biotin binding-site residues of 
rhizavidin, a biological streptavidin dimer (243), into a streptavidin monomer. Other 
stabilizing mutations were introduced based on rational design (Figure 32). The resultant 
monomer (mSA) has 55% sequence identity with streptavidin and 57% identity with 
rhizavidin. The mutations improved the affinity of the monomer for biotin by 13-fold and 






 One unanticipated feature of mSA is rapid dissociation of bound biotin, which 
limits the usefulness of the streptavidin monomer for the aforementioned applications. To 
overcome this issue, the Park lab introduced an additional mutation, L25H, which slowed 




, and yielded a two-fold 
improvement in affinity (Kd=0.52 nM) (6). Besides its potential suitability for a variety of 
research applications, a major practical improvement for mSA2 was the addition of an 
MBP fusion tag to the N-terminus (MBP-mSA2) to allow for the expression of soluble 
protein, instead of inclusion bodies.  
The MBP-mSA2 plasmid was generously gifted to us by Dr. Sheldon Park to 
explore its use as a crystallization chaperone. Since monomeric streptavidin can bind 
biotin with high affinity, is very stable, and easily crystallized, we hypothesized mSA2 
could potentially be a general crystallization chaperone for biotinylated proteins. As 
described in this chapter, our system uses biotin ligase (BirA) to enzymatically 
 
Figure 32 Design of monomeric streptavidin based on rhizavidin dimer 
(a) Alignment of streptavidin and rhizavidin sequences based on structure. Residues in the 
final hybrid mSA are in bold and the engineered disulfide bond is shown in yellow. (b) The 
modelled structure of mSA. Residues of streptavidin origin are in cyan, rhizavidin origin are 
in green, and those common to both proteins are in yellow. The residues that differ from both 
streptavidin and rhizavidin are not shown. Biotin is in purple van der Waals spheres (6). 







biotinylate a specific lysine residue within a 15 amino acid tag (GLNDIFEAQKIEWHE, 
Avi-tag), which is inserted into a loop within the test protein of interest, in this case, 
MBP (MBPavi). Complexation of mSA2 bound to MBPavi and crystallization trials are 
discussed.  
5.1.1 Individual contributions to the work 
The use of monomeric streptavidin as a crystallization chaperone has been an idea 
in the lab since its inception. Dr. Derrick Watkins and Lindsey Porter experimented with 
converting the tetrameric streptavidin to monomeric and refolding from inclusion bodies. 
Dr. Park then shared the plasmid for an early, less stable version of streptavidin monomer 
(Tr-mStrav).  By using Lindsey’s protocols, I was successful with the refolding of Tr-
mStrav and binding to a chemically biotinylated membrane protein (data not shown) with 
the help of 2013 REU summer student Rachel Wills. The project in its current form has 
been optimized by me and I planned and conducted all the experiments presented in this 
chapter.  
5.2 METHODS 
5.2.1 Protein expression and purification 
5.2.1.1 BirA BL21 expression and amylose-affinity chromatography 
BirA plasmid (pET-28a/BirA) was generously provided by Dr. Sheldon Park and 
encodes MBP-BirA fusion, with an N-terminal hexahistidine-tag and a TEV protease site 
between MBP and BirA. Expression and purification was carried out as previously 
reported (244), with some exceptions. Briefly, after transformation of the plasmid into E. 
coli BL21(DE3), a single colony was placed in 100 mL LB containing 50 µg/mL 




starter culture was diluted 1:100 in each 1 L fresh LB culture supplemented with 50 
µg/mL kanamycin, and cells were grown at 28 °C with shaking at 225 RPM until the 
OD600 reached 0.6. The temperature was then dropped to 18 °C, and expression was 
induced by the addition of IPTG to a final concentration of 1 mM. Cells were cultivated 
for 22 hours then harvested by centrifugation at 4225 x g for 10 minutes. Cell pellet was 
flash frozen in liquid nitrogen and stored at -80 °C.  
Cells mass corresponding to ~3 L culture were thawed and resuspended in BirA 
cell lysis buffer (25 mM Tris pH 8, 200 mM NaCl) and lysed by French press using 
18,000 PSI cell pressure, passing through twice. Lysate was rocked at 4 °C for 30 
minutes then centrifuged at 47,800 x g for 40 minutes. Lysate was then purified using 
either amylose- or Ni
2+
-affinity chromatography. For amylose-affinity chromatography, 
BirA cell lysis buffer was used for the wash, and cell lysis buffer supplemented with 20 
mM maltose was used for elution. For Ni
2+
-affinity chromatography, cell lysis buffer was 
supplemented with 20 mM imidazole for the wash, and 400 mM imidazole for the elution 
(Figure 34a). Since BirA activity is inhibited by NaCl, the purified protein is then 
exchanged into 25 mM Tris pH 8 via gel filtration on Superdex 75 16/60 column or by 
using an 30K MWCO Amicon Ultra centrifugal filter. MBP-BirA fusion protein does not 
need to be cleaved for biotin ligase activity. Henceforth, BirA refers to the fusion MBP-
BirA . Purified BirA can be stored at 4 °C for at least 2 weeks. For longer term storage, 
BirA in 50% glycerol can be stored at -20 °C.  
5.2.1.2 Molecular biology, BL21 expression and purification of MBPavi 
The pAK400 expression vector with the MBP-KEE gene (see Section 3.2.5) was 




amino acid Avi-tag GLNDIFEAQKIEWHE using primers listed in Table 17; see Figure 
33 for alignment of relevant residues of WT MBP with each round of SDM for MBPavi 
prepared using Clustal Omega (150). Plasmid fidelity is confirmed by DNA sequencing 
(MWG Operon, www.operon.com).  
Table 17 Primers used for both rounds of SDM to make MBPavi 
 Forward Primer Reverse Primer 
SDM Round 1 
MBP-Avi_Rd1_For 
GCT GAT TGC TGC TGA CGG 
GGG TTA TGC GTT CAA GGG 
CCT GAA TGA TAT TTT TGA 
AGC GCA GGA ATA CAT GCC 
CAT GGA GGA CAT TAA AGA 
CGT GGG 
MBP-Avi_Rd1_Rev 
CCC ACG TCT TTA ATG TCC 
TCC ATG GGC ATG TAT TCC 
TGC GCT TCA AAA ATA TCA 
TTC AGG CCC TTG AAC GCA 
TAA CCC CCG TCA GCA GCA 
ATC AGC 
SDM Round 2 
MBP-Avi_Rd2_For 
GCG CCA GCG TTA TCC ACG 
CCC ACG TCT TTA ATG TCT 
TCA TGC CAC TCG ATT TTC 
TGC GCT TCA AAA ATA TCA 
TTC AGG CCC TTG AAC G 
MBP-Avi_Rd2_Rev 
CGT TCA AGG GCC TGA ATG 
ATA TTT TTG AAG CGC AGA 
AAA TCG AGT GGC ATG 
AAG ACA TTA AAG ACG 




MBPavi was expressed in the same manner as Fab/EE (see Section 3.2.1, (120)). 
Briefly, MBPavi was expressed in E. coli BL21(DE3). 2 mL LB (Fisher) culture 
 
Figure 33 Alignment of WT MBP and MBPavi after each round of SDM 
Clustal Omega alignment of WT MBP with MBPavi after SDM round 1 (a) and round 2 (b). 






supplemented with 34 µg/mL chloramphenicol was inoculated with a single colony and 
incubated for ~4 hours at 37 °C with shaking at 225 RPM. The starter culture was diluted 
1:100 in 500 mL Terrific Broth (TB, Fisher) in a 2 L baffled flask and grown overnight 
with shaking at 225 RPM and 25 °C. Cells were pelleted at 4200 x g for 10 minutes and 4 
°C, then the cell pellet was resuspended in 500 mL fresh TB in 2 L flask and incubated 
for 1 hour at 25 °C, 225 RPM before inducing expression with 1 mM IPTG for 4.5-5 
hours. Cells were pelleted and flash frozen in liquid nitrogen before placing in -80 °C 
freezer. Cells were then thawed and resuspended in 25 mM Tris pH 8, 250 mM NaCl and 
lysed by passing through French press at least twice at 18,000 PSI cell pressure. Cellular 
debris was pelleted by ultracentrifugation at 181,000 x g and lysate was purified by 
amylose-affinity chromatography using the same buffers as for BirA (Figure 34b).  
5.2.1.3 MBP-mSA2 BL21 expression, purification, and cleavage 
The pET-28a vector containing the gene for MBP-mSA2 was generously 
provided by Dr. Sheldon Park. pET-28a/MBP-mSA2 plasmid was transformed into 
BL21(DE3) E. coli cells and a single colony was used to inoculate 100 mL LB containing 
50 mM KH2PO4, 50 mM Na2HPO4, 25 mM (NH4)2SO4, 1 mM MgSO4, 0.5% glycerol, 
1% glucose, and 50 µg/mL kanamycin. After overnight growth at 37 °C and 225 RPM, 
the starter culture was diluted 1:100 in 1 L LB containing 50 mM KH2PO4, 50 mM 
Na2HPO4, 25 mM (NH4)2SO4, 1 mM MgSO4, 0.5% glycerol, 0.5% glucose, and 50 
µg/mL kanamycin. The cultures were incubated at 37 °C and 225 RPM until the OD600 
reached 0.8-1.0 at which point expression was induced by the addition of 50 µM IPTG. 




centrifugation at 4300 x g for 10 minutes and flash frozen in liquid nitrogen before 
storing at -80 °C. 
Cells (~5 g) harboring MBP-mSA2 were thawed on ice and resuspended in 15-25 
mL MBP-mSA2 cell lysis buffer (25 mM Tris pH 8, 150 mM NaCl, 1 mM EDTA, 10% 
glycerol, 0.2% Triton X-100, 0.2 mg/mL lysozyme, 0.9 mM biotin, and Roche protease 
inhibitor) and incubated on ice for 30 minutes prior to lysis by French press at 18,000 
PSI. Cellular debris was pelleted by centrifugation at 18,000 x g for 20 minutes at 4 °C. 
Cell lysate was purified by amylose-affinity chromatography using 50 mM Tris pH 8, 
150 mM NaCl, 1 mM EDTA, 0.9 mM biotin as the wash buffer and elution buffer 
containing 20 mM maltose (Figure 34c).  
5.2.1.4 MBP-mSA2 TEV cleavage 
Purified MBP-mSA2 was exchanged into 50 mM Tris pH 8, 150 mM NaCl, 0.9 
mM biotin, 0.5 mM EDTA and 1.0 mM DTT and concentrated to ~10 mg/mL using a 
30K MWCO Amicon Ultra centrifugal filter. TEV protease (in PBS, see Chapter 2 for 
TEV protease expression and purification) was added in a 10:1 MBP-mSA2:TEV 
protease mass ratio. The sample was incubated at room temperature for 1 hour, then 
heated in a 75 °C water bath for 10 minutes. After cooling sample on ice for about 2 
minutes, the precipitate was pelleted by centrifugation at 10,000 x g for 10 minutes. 
Supernatant was further purified on a Superdex 75 16/60 gel filtration column, and 
fractions containing cleaved mSA were concentrated in a Amicon Ultra centrifugal filter 







Figure 34 Purification of BirA, MBPavi, and MBP-mSA using amylose resin 
(a) BirA, (b) MBPavi, and (c) MBP-mSA were purified using amylose resin. Each gel shows 
the cell debris (pellet) after lysis and centrifugation, the cell lysate before purification, two 
flowthrough fractions, and elution fractions from the amylose purification. Fraction locations 
are marked with black dots along the x-axis of the chromatogram. Elution fractions were 










5.2.2 Enzymatic biotinylation of MBPavi using BirA and purification of 
biotinylated MBPavi 
Since BirA activity is inhibited by NaCl, MBPavi is exchanged into 25 mM Tris 
pH 8 prior to biotinylation. In advance, 10X Biomix A (100 mM Tris pH 8), 10X Biomix 
B (100 mM adenosine triphosphate (ATP), 100 mM magnesium acetate, 500 µM D-
biotin) is prepared and stored at -80 °C. The biotinylation reaction contains 1X Biomix 
A, 1X Biomix B, 40 µM MBPavi, and 500 µg/mL MBP-BirA, and is carried out for 12-
16 hours at 30 °C.  
To remove excess biotin prior to purification of bMBPavi, the BirA/MBPavi 
mixture was buffer exchanged into avidin wash buffer (50 mM Tris pH 8, 150 mM NaCl) 
then loaded onto a column packed with 15 mL Monomeric Avidin UltraLink Resin 
 
Figure 35 Cleavage of mSA and gel filtration over Superdex 75 column 
mSA was cleaved, heated, and sample was run over Superdex 75 column to remove 
impurities. SDS-PAGE samples are as follows: sample immediately following addition of 
TEV protease (Cleavage, T=0), sample 1 hour after adding TEV protease (Cleavage, T=1 hr), 
sample after heating for 10 minutes at 75°C (After heating), sample after centrifuging at 10K x 





(Pierce, #53146) on an AKTA Pure FPLC instrument. The column was then washed with 
avidin wash buffer until the A280 was near baseline then washed with 5 column volumes 
(CV) avidin elution buffer (50 mM Tris pH 8, 150 mM NaCl, 2 mM biotin), followed by 
5 CV avidin regeneration buffer (50 mM glycine pH 2.5). Peak elution fractions were 
pooled and concentrated in 10K Amicon Ultra centrifugal filter.  
 
5.2.3 Complexation of bMBPavi with mSA 
bMBPavi was exchanged into either 25 mM Tris pH 8 or 25 mM Tris pH 8, 150 
mM NaCl TBS to remove excess biotin. Protein concentration was assessed using Beer’s 
law where absorbance was measured at 280 nm using a Nanodrop 2000 UV/Vis 
spectrophotometer, and molecular weight, and extinction coefficients calculated by 
ExPASy ProtParam (149) based on protein sequences. Protein purity was accessed by 
12% SDS-PAGE. bMBPavi and mSA were incubated on ice in a 4:1 mSA2:bMBPavi 
molar ratio for 1 hour prior to injection onto a Superdex 75 16/60 gel filtration column 
     
Figure 36 Purification of biotinylated MBPavi using avidin resin 
MBPavi is biotinylated using BirA and the BirA/MBPavi mixture is purified over monomeric 
avidin resin. Fraction locations are marked with black dots along the x-axis of the purification 
trace. Elution buffer contains biotin to elute the biotinylated protein, and the regeneration 





using either 25 mM Tris pH 8 or TBS as the mobile phase. Samples were evaluated on 
SDS-PAGE and fractions containing both bMBP and mSA were concentrated in a 3K 
Amicon Ultra centrifugal filter for crystallization trials.  
5.2.4 Crystallization trials of bMBP:mSA2 complex 
After complex purification over gel filtration using either TBS or Tris pH 8 as the 
running buffer, fractions containing the complex were pooled and concentrated in a 3K 
MWCO Amicon Ultra centrifugal filter. Crystal trays were prepared using commercial 96 
well screens (Hampton, Emerald Biosystems) and an Art Robbins Gryphon drop setter. 
Starting protein concentration ranged from 5 mg/mL to 21.9 mg/mL, and concentration 
was measured using Nanodrop 2000 with the sum of molecular weights and extinction 
coefficients as calculated by ExPASy ProtParam (149). The crystallization drop 
contained 0.3 µL protein sample and 0.3 µL crystallization solution from a commercial 
96-well screen (Hampton or Emerald Biosystems). All trays were stored in a 20 °C 
incubator. Drops were imaged using a Rigaku Minstrel DT and visualized with both 
visible and UV light settings.  
5.3 RESULTS 
5.3.1 Insertion of the Avi-tag into MBP 
MBP was chosen as the test protein because it is easily crystallized (a BLASTp 
(144) search of the E. coli MBP sequence returns >100 structures, see (245-247) for 
recent examples), easily expressed in E. coli as evidenced by the use of MBP as a fusion 
protein to ease expression of difficult proteins in E. coli (248), and already available in 
several plasmids in the lab. The insertion location for the Avi-tag was chosen based on 




MBPavi, and Figure 37 for Avi-tag placement in MBP). After insertion, MBPavi was 
still easily expressed, and the biotinylation was successful, so other Avi-tag insertion 
locations were not explored.  
 
5.3.2 Purification of components 
All components critical to the success of the project, namely, MBPavi, MBP-
mSA2, and BirA were successfully expressed and purified in high yield and purity 
(Figure 35). BirA was used to enzymatically biotinylate MBPavi (Figure 36), and MBP-
mSA2 was cleaved to free mSA2 (Figure 35). bMBPavi and mSA2 were complexed over 
gel filtration (Figure 38), and the isolated complex was used in crystallization trials.  
Though each protein was obtained with high purity, some facets of the protocol 
could be optimized. First, the MBP-mSA2 cleavage reaction does not go to completion 
(see Figure 35, lane “cleavage, T=1 hr”), even after 24 hour room temperature incubation 
(data not shown). The cause of this is unknown, and the amount of protein lost is 
considered negligible. The sample is then heated to precipitate TEV protease, uncleaved 
MBP-mSA, and cleaved MBP. Heating the sample also causes protein loss (compare 
 
Figure 37 MBP structure showing placement of Avi-tag 
Structure of MBP (green) was rendered in Pymol (1) from the MBP portion of PDB ID 3MQ9 
(3). 6 residues were replaced by the Avi-tag and are colored blue. The other 9 residues were 





mSA bands of Figure 35, lane “cleavage, T=1 hr” and lane “After pelleting”), but the 
sample is difficult to purify without heating due to the overlapping peaks of MBP and 
mSA during gel filtration.  
The avidin purification of bMBPavi could also be optimized. The avidin column 
flowthrough should contain a uniform peak of BirA and unbiotinylated MBPavi, but 
Figure 36, lane 1 shows mostly BirA and the shoulder of the flowthrough peak, Figure 
36, lane 2 contains MBPavi. The likely cause of this is that the capacity of the avidin 
resin has been reached so the rest of the bMBPavi cannot bind the column. This issue 
could be rectified easily by increasing the volume of monomeric avidin resin or 
separating the sample into two purification runs.  
5.3.3 Complexation of biotinylated MBPavi with monomeric streptavidin 
Because the lack of NaCl in a protein crystallization buffer allows the salt in the 
crystallization condition to have more impact, the bMBP:mSA2 gel filtration was done in 
both Tris pH 8 (without salt) and TBS. In both cases, the first small peak contained a 
small amount of aggregated mSA, the second peak contained bMBP:mSA2 complex, the 
shoulder of the second peak contained uncomplexed bMBP, and the last peak contained 
mSA (Figure 38). The elution volumes of the complex and the individual proteins were 
significantly different when Tris pH 8 was used instead of TBS pH 8. This is likely due to 
non-specific interactions of the protein with the gel filtration matrix in the condition 
without NaCl.  
In the size exclusion chromatography of the complex, the sample contains a 4:1 
ratio of mSA:bMBP. An excess of mSA2 was originally chosen so that no bMBP peak 




of the mSA2, however, is not able to bind free bMBP so some percentage of the mSA 
still has bound biotin (Figure 38). Biotin can be dissociated from streptavidin by low pH 
or elevated temperature, so a buffer exchange of mSA into 50 mM glycine pH 2.5 at 4 °C 
or 25 mM Tris pH 8 at 40 °C should eliminate much of the bound biotin and increase the 
yield of bMBP:mSA2 complex.  
 
5.3.4 Progress in the crystallization of bMBP:mSA2 complex 
Crystallization trays of bMBP:mSA complex were prepared using both Tris pH 8 
and TBS as the protein crystallization buffer (12 x 96 conditions from commercial 
screens and 3 x 24 conditions from homemade screens, ~1200 conditions total). As a 
general rule of thumb, about 50% of wells in a sparse matrix tray should contain protein 
precipitate immediately after the tray is prepared. The optimal concentration of protein in 
 
Figure 38 Gel filtration and SDS-PAGE of the bMBP:mSA complex 
(a) purified mSA and bMBP were mixed and incubated on ice for 1 hour prior to injection on a 
Superdex 75 column. The mobile phase was either 25 mM Tris pH 8 (red) or 25 mM Tris pH 8, 
200 mM NaCl (blue). (b) SDS-PAGE of samples prior to injection on the GF column (left) and 
fractions from each GF run (middle and right). Fraction locations are marked with either red or 
blue dots on the x-axis of the GF trace. The middle gel represents samples from the GF run in TBS 




a crystallization buffer without NaCl was much lower (6.7 mg/mL) than that of protein in 
TBS crystallization buffer (>22 mg/mL).  
Crystallization trays of MBPavi alone were also prepared to test if the Avi-tag 
hinders crystallization. One well did contain crystals, though they diffracted poorly and 
the structure was not determined (data not shown).  
5.4 DISCUSSION 
Though separately MBP and streptavidin are soluble, easily crystallized proteins, 
crystallization trials of the bMBP:mSA2 complex were unsuccessful. As noted with the 
insertion of the EE tag in Chapter 4, the insertion of the Avi-tag likely increases the 
flexibility of the loop which negatively impacts the crystallization. After several 
crystallization trials using different commercial screens and a range of protein 
concentrations, no complex crystals were identified.  
Though the crystallization of bMBPavi:mSA2 was unsuccessful here, as indicated 
in Chapter 4, we are still optimistic that this approach could be successful. A BLASTp 
(144) search of the 15 amino acid Avi-tag reveals 3 structures with the Avi-tag modeled 
into the published structure. In PDB ID 2BCK, amino acids GLNDIF were modeled into 
the structure (249). Similarly, in PDB ID 2YF6, GL was modeled (250). In PDB ID 
4L79, all 15 amino acids of the Avi-tag were modeled, the first 9 of which were in an 
alpha helix and the last 6 were in a loop region (251). In all 3 structures, the modeled 
Avi-tag forms crystal contacts with neighboring molecules, perhaps locking the 
disordered structure into a specific confirmation (Figure 39). Without stabilizing crystal 





5.4.1 Concluding remarks and future directions 
With the available PDB structures indicating that the Avi-tag is flexible, another 
approach may be needed in order to use monomeric streptavidin as a crystallization 
chaperone without the negative effects of the flexibility of the 15 amino acid Avi-tag 
inserted into the protein of interest. A 13 amino acid miniprotein 
(RCCHPQCGAVEECR) was designed by the lab of Dr. Robert O. Fox of the University 
 
Figure 39 Structures of 3 partial or full Avi-tags from the PDB 
PDB ID of the structure is shown in the upper left corner of each image. The asymmetric unit 
is colored by chain (blue and green) with the Avi-tag in yellow sticks with the amino acid 
labelled in black. Symmetry related molecules forming crystal contacts with the Avi-tag are 




of Texas Medical Branch as a ligand for tetrameric streptavidin in place of biotin. 
Though the work was never published, the crystal structure in the PDB (PDB ID 1HQQ 
(2)) reveals that the miniprotein has a rigid structure with all the cysteines forming 
disulfide bonds, and the N- and C-termini are within 10 Å of one another. The 
miniprotein streptavidin ligand could theoretically be inserted into a loop of a protein of 
interest and the rigid structure of the miniprotein tag could allow for crystallization of the 
miniprotein-tagged:mSA2 complex. As shown here, our Avi-tag approach may have 
added conformational heterogeneity in the crystallization drop, but perhaps a similar, 
more rigid, approach could prove effective.  
  
 
Figure 40 Streptavidin in complex with 13 amino acid miniprotein ligand 
A monomer of tetrameric streptavidin is shown in cyan cartoon, with the other three subunits 
omitted for clarity. The 13 amino acid miniprotein ligand is shown as white sticks, with each 
side chain labelled. N- and C-term are also labelled, and are 9.8 Å away from one another. 





CHAPTER 6: MOLECULAR BASIS OF NOVEL 1-
DEOXYGALACTONOJIRIMYCIN ARYLTHIOUREA 
PHARMACOLOGICAL CHAPERONES BINDING TO 
ΑLPHA GALACTOSIDASE A FOR THE TREATMENT 
OF FABRY DISEASE 
6.1 INTRODUCTION 
Fabry disease (FD) is an X-linked lysosomal storage disorder (LSD) resulting 
from mutations in the GLA gene which encodes glycoside hydrolase α-galactosidase A 
(α-Gal A) (252). Mutations in α-Gal A result in the aggressive accumulation of 
glycosphingolipids in the lysosome, mainly globotriaosylceramide (Gb3). Gb3 
accumulation could result in minor to severe symptoms, including neuropathic pain, 
gastrointestinal issues, hearing loss, cardiomyopathy, skin angiokeratomas, and renal 
problems. FD incidence is estimated to be around 1:100,000 live births, though some 
believe that is an underestimation (252), and incidence in Italian and Taiwan male 
newborns is much higher (1:3100 and 1:1250, respectively) (253, 254).  
The three-dimensional crystal structure of α-Gal A shows two domains in each 
monomer. Residues 32-328 make up the N-terminal domain, and residues 329-421 fold 
into a C-terminal domain containing eight antiparellel β-strands packed into a β 
sandwhich. The active site is contained within the N-terminal domain, and 15 residues 
come together to form the pocket (Trp 47, Asp 92, Asp 93, Tyr 134, Cys 142, Lys 168, 
Asp 170, Cys 172, Glu 203, Leu 206, Tyr 207, Arg 227, Asp 231, Asp 266, and Met 267) 
(255). 13 of those residues made direct hydrogen bonding interactions with galactose 
(256, 257). The catalytic nucleophile is Asp 170 and the catalytic acid/base is Asp 231 




(Human Gene Mutation Database, www.hgmd.cf.ac.uk), including all 13 residues 
interacting with galactose. About 60% of all known mutations result in unstable α-Gal 
which is targeted for degradation in the ER.  
In 2001, enzyme replacement therapy (ERT) was introduced for the treatment of 
FD where purified enzyme is injected into the patient biweekly (252, 258, 259). Drug 
efficacy has been confirmed in FD patients, but problems include stability of the protein 
in blood, and patient immunological response (260). Alternatively, pharmacological 
chaperones (PCs, the use of “chaperone” here is unrelated to its use in previous chapters) 
are being tested for FD. PCs are small molecules which bind to the destabilized enzyme 
in the ER, allowing proper folding and trafficking to the lysosome. Once inside the 
lysosome, the PC dissociates from α-Gal A, and its glycoside hydrolase activity is 
restored.  
Competitive inhibitors act as PCs for α-Gal A. A mimic of the terminal galactose 
unit of Gb3, deoxygalactonojirimycin (DGJ), has been shown to enhance the residual 
activity of α-Gal A by stabilizing the mutant enzyme and allowing trafficking to the 
lysosome (261, 262). DGJ is a low molecular weight molecule, can be administered 
orally, is free from immunological reactions, and is currently in clinical trials for the 
treatment of FD (252, 263). However, DGJ is largely protonated at physiological pH, and 
is highly hydrophilic, making it difficult to pass through biological membranes. 
Previously, C1- and N-substitutions to increase amphiphilicity has been done, with 
limited success due to a significant decrease in the affinity of α-Gal A for the chaperone 
(264). A look at the DGJ-bound α-Gal A crystal structure reveals a hydrogen bonding 




likely broken with N-substitutions (Figure 41a). In the case of galactose, the interaction 
is stabilized by Asp 231, which is not possible for a C1 carbon substituent (Figure 41b). 
We hypothesize that the Asp 231 interaction could be maximized with a DGJ-
arylthiourea, with the N’H proton being the hydrogen bond donor (Figure 41c).  
 
In this chapter, the synthesis of 4 DGJ-ArTs is discussed, as well as the molecular 
basis for DGJ-ArT binding based on an X-ray crystal structure of DGJ-ArT-bound α-Gal 
A. Inhibition and activity assays are done to evaluate the potential of DGJ-ArTs for the 
treatment of FD.  
6.1.1 Individual contributions to the work 
This work is highly collaborative between the laboratories of Katsumi Higaki at 
Tottori University in Yonago, Japan, José García Fernández at Universidad de Sevilla in 
Sevilla, Spain, and Raquel Lieberman at Georgia Tech. Yi Yu and Katsumi Higaki 
performed inhibition and stabilization assays in vitro. Yu Yi, Katsumi Higaki and 
Takahiro Tsukimura performed chaperone test and cell toxicity test on cultured 
fibroblasts. Yi Yu, Katsumi Higaki, and Naoe Nakasone performed 
transfection/chaperone test on COS7 cells, immunofluorescence analysis of anti-Gb3 and 
 
Figure 41 Design criteria for the novel FD PCs, DGJ-ArTs 
Key hydrogen bonding interactions between the catalytic residues D170 and D231 with DJG 





western blot analyses. Katsumi Higaki, Eiji Nanba and Kousaku Ohno designed the 
overall biological study. Hitoshi Sakuraba and Yoshiyuki Suzuki supervised the work. 
Dr. Jason Drury crystallized the protein, performed crystal soaking experiments, and 
collected the x-ray data. I did all the data processing and model building, including 
modeling the inhibitor into the active site and analysis of hydrogen bonding interactions. 
Members of the García Fernández Lab performed remaining experiments.  
6.1.2 Publication resulting from this work 
This research was published in the journal ACS Chemical Biology issue 9 in 2014 
(266). This chapter was adapted with permission from Yu et al., ACS Chemical Biology, 
2014. 9(7): p. 1460-1469. http://pubs.acs.org/doi/abs/10.1021/cb500143h Copyright 
(2014) American Chemical Society.  
6.2 METHODS 
6.2.1 Synthesis of DGJ-arylthioureas and other DGJ Derivatives 
1-Deoxygalactonojirimycin (DGJ) was prepared following a protocol previously reported 
(267). The 4 novel DGJ-ArT pharmacological chaperones (N’-(1-naphthyl) (DGJ-NphT), 
N’-(p-methoxyphenyl) (DGJ-pMeOPhT), N’-(p-methylthiophenyl) (DGJ-pMeSPhT), and 
N’-(p-fluorophenyl) (DGJ-pFPhT), Figure 42) were synthesized by reacting the 
substituent component (1-naphtyl, p-methoxyphenyl, p-methulthiophenyl, or p-
fluorophenyl isothiocyanate, respectively) with DGJ (Figure 43). Two additional DGJ 
derivatives were synthesized for comparative purposes (Figure 42). The bicyclic 
isothiourea-type derivitave 5N,6S-(p-fluorophenylimino methylidene)-6-thio-1-




monocyclic thiourea precursor DGJ-pFPhT (Figure 43). DGJ N’-benzylthiourea (DGJ-
BnT) was prepared by reaction of DGJ and benzyl isothiocyanate.  
 
 
6.2.2 Cell culture, transfection, and pharmacological chaperone test 
Human skin fibroblasts and COS7 cells were cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) with 10% FBS. Immortalized human fibroblast lines were 
 
Figure 43 Synthesis of DGJ-ArT pharmacological chaperones and bicyclic DGJ 
derivative 
Reaction conditions: a) RNCS, pyridine, diethylamine, room temperature for 18 hours, 47-
94% yield; b) HCl, methanol, room temperature for 12 hours,  45-99% yield. 
 




established by transfecting SV40 large T cDNA expression vector, pET321-T (268). To 
test the pharmacological chaperones, human fibroblasts were cultured in DMEM with or 
without the chaperone for 96 hours as described previously (269, 270). The chaperones 
were exposed to the immortalized human fibroblast cells for 48 hours. Lipofectamine 
2000 was used for the transfection of COS7 cells with wild-type and mutant α-Gal A 
cDNA (271). After 5 hours, the medium was replaced with fresh medium containing or 
lacking the pharmacological chaperones and cells were incubated for 48 hours. 
Cytotoxiticy of the compounds in the human fibroblast cells was evaluated using the 
lactate dehydrogenase (LDH) cytotoxicity assay.   
6.2.3 Measurement of enzyme activities in the lysosome 
4-MU-conjugated substrates were used to measure lysosomal enzyme activities 
(4-MU-conjugated α-D-galactopyranoside for α-Gal A, β-D-galactoside for β 
galactosidase (β-Gal), N-acetyl-β-D-glucosaminide for total hexosaminidase (Hex) and α-
N-acetyl-D-galactosaminide for α-N-acetylgalactosaminidase (α-NAGA)). For the α-Gal 
assay, 10 µL cell lysate (in 0.1% Triton X-100 in dH2O) was mixed with 20 µL 4-MU 
substrate (5 mM 4-MU α-D-galactopyranoside and 0.1 M N-acetyl-D-galactosamine in 
0.1 M citrate buffer, pH 4.5). The mixture was incubated at 37 °C for 1 hour and 
terminated with the addition of 0.2 M glycine-NaOH, pH 10.7. The free 4-MU was 
measured with a Tecan Infinite F500 fluorescence plate reader using excitation 
wavelength 340 nm and emission wavelength 460 nm. Protein concentration was 
measured using Wako Protein Assay Rapid Kit, and enzyme activity was normalized by 
protein concentration.  




0.1% Triton X-100 extracts from normal human skin fibroblasts were mixed with 
4-MU substrates in absence or presence of DGJ derivatives (269) for the inhibition assay. 
For heat-induced degradation, extracts were incubated at 48 °C for the time indicated in 
0.1 M citrate buffer, pH 7. The reaction was terminated with the addition of 0.1 M citrate 
buffer, pH 4.5 and the enzyme activity was measured as in section 6.2.3.  
6.2.5 Crystallization and X-ray data collection of α-Gal A in complex with DGJ-
pFPhT 
Apo α-Gal A (10 mg/mL) was crystallized at pH 4.5 as described previously 
(256). 0.15 µL of 1 mM DGJ-pFPhT encapsulated in β-cyclodextran (βCD) (272) was 
added directly to the crystallization drop and incubated for 4.5 hours at room 
temperature. Crystals were cryocooled in mother liquor supplemented with 30% ethylene 
glycol. Diffraction data were collected at SER-CAT beamline 22-ID at the APS in 
Argonne, Illinois. Data were indexed, integrated, and scaled using HKL-2000 (273) in 
space group P3221. Molecular replacement using a single chain of apo α-Gal A (PDB ID 
3GXN (256)) was performed in Phaser (200) and the model was refined using Phenix 
(204). eLBOW (274) within Phenix was used to generate the restraints of the DGJ-pFPhT 
molecule using coordinates generated in PRODRG (275). The final occupancy of DGJ-
pFPhT within the α-Gal A structure is 0.6. The crystallographic statistics can be found in 




Table 18 Data collection and refinement statistics for α-Gal A in complex with DGJ-pFPhT 
pharmacological chaperone 
Parameter Α-Gal A in complex with DGJ-pFPhT 
Data collection 
 
Beamline source APS 22-ID 
X-ray wavelength (Å) 1.0 
Resolution (Å) 38.68  - 2.549 (2.64  - 2.549) 
Space group P 32 2 1 
Unit-cell parameters 
 
a, b, c (Å) 90.783 90.783 217.382 
α, β, γ (°) 90 90 120 
Total No. of reflections 180519 
No. of unique reflections 33780 (2979) 
Multiplicity 5.3 (3.6) 
Completeness (%) 97.25 (87.34) 
〈 I/σ(I)〉 15.14 (2.56) 
Rsym (%) 0.105 (0.471) 
Refinement statistics 
 
Final Rcryst 0.1871 (0.2628) 
Final Rfree
a
 0.2317 (0.3118) 






Bonds (Å) 0.007 
Angles (°) 0.93 










Most favoured (%) 97 
Outliers (%) 0 
a
Rfree is calculated for a randomly chosen 5% of reflections which were not used for 
structure refinement  
b





6.2.6 Immunofluorescence staining 
The cells were fixed to coverslips with 4% paraformaldehyde in PBS, then 
permeabilized with 0.1% Triton X-100 in PBS, and incubated with the primary antibodies 
for 1 hour. Bound primary antibodies were detected using secondary antibodies 
conjugated with Alexa-Fluor. Fluorescence images were collected using a Leica TSC SP-
2 confocal laser microscope. All of the procedures were carried out at room temperature. 
Gb3 intensity was measured using Leica confocal software and intensity was normalized 
using 4',6-diamidino-2-phenylindole (DAPI) intensity. For each experiment, over 100 
cells in 10 randomly collected images were evaluated. 
6.2.7 Immunoblotting 
Cultured cells were lysed by sonication in 10 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, and a Roche protease inhibitor cocktail. Detergent-
resistant membrane microdomains were obtained by centrifugation at 100,000 x g for 30 
minutes in 1% Triton X-100. Procedure was carried out at 4 °C. Immunoblotting was 
performed as described previously (276) and signal from HRP-conjugated secondary 
antibodies were visualized using enhanced chemiluminescence (ECL) detection kit (GE 
Lifescience). Images were obtained using Fujifilm LAS-4000 lumino image analyzer. 
6.3 RESULTS 
6.3.1 Comparison of α-Gal A crystal structures in complex with DGJ and DGJ-
pFPhT 
The 2.55 Å resolution crystal structure of α-Gal A in complex with DGJ-pFPhT 
shows the glycomimetic in the active site as expected. The 2Fo-Fc density is clear for the 




linker (Figure 44a). The orientation of the iminosugar and side chains involved in 
hydrogen bonding are similar to that of DGJ in PDB ID 3GXT (Figure 44b), and the 
polypeptide chain is largely unchanged from other ligand-bound α-Gal A structures, as 
seen previously (256). Hydroxyl groups OH-2, OH-3, OH-4, and OH-6 of DGJ-pFPhT 
are involved in extensive hydrogen bonding network with α-Gal A residues Asp 92, Asp 
93, Lys 168, Arg 227, and the catalytic nucleophile Asp 170, and the catalytic acid/base 
Asp 231 (Figure 44c). Similar hydrogen bonding pattern is seen with DGJ, with the 
exception of Asp 170 and Asp 231, as predicted (Figure 44d). Hydrogen bonding 
distances for DGJ-pFPhT are slightly longer than hydrogen bonds for DGJ and the 
flurorbenzyl ring is nestled among hydrophobic residues Leu 206, Ala 230, and Tyr 207. 
The cocrystal structure confirms that the desired orientation of the pharmacological 
chaperone within the α-Gal A active site was achieved, with the predicted hydrogen 
bonding interaction between Asp 231 and the N’H proton.  
6.3.2 Effects of DGJ arylthiourea compounds on α-Gal A in vitro 
The inhibitory activity of the DGJ-ArTs was tested in human skin fibroblast cells 
and compared to the activity of DGJ and the two DGJ derivatives, bicyclic isothiourea 
pFPhIM-DGJ and alkylthiourea DGJ-BnT (Figure 42, Figure 45a). IC50 values were 
calculated from the inhibition assay and range from 0.0083 to 1.6 µM for the 4 DGJ-ArTs 
at pH 5 (Table 19). The inhibitory effect of the two control DGJ derivatives, pFPhIM-
DGJ and DGJ-BnT, are 3- to 4-fold less than the inhibitory potential of the 4 designed 
DGJ-ArTs. The potency of the DGJ-ArT inhibitors increases from pH 7 to pH 5 by 4.3 to 




No inhibition was observed for β-Gal and Hex, and moderate inhibition was detected for 
α-NAGA (Figure 45b).  
The ability of the DGJ-ArTs to protect the heat-induced inactivation of α-Gal A 
was measured in normal fibroblasts. After incubating cell extracts for 40 minutes at 48 
°C, α-Gal A retained about 20% of its initial activity. The 4 DGJ-ArTs were able to 
protect against the heat inactivation, with the most effective compounds being DGJ-
pMeOPhT and DGJ-pMeSPhT, with 95 and 85% protection after 1 hour incubation and 
30 µM concentration. The designed DGJ-ArTs were significantly more effective than 
reference pFPhIM-DGJ, and slightly more effective than DGJ-BnT (Figure 46).  
6.3.3 The activity of α-Gal A is increased in normal and FD fibroblast cells after 
treatment with DGJ-ArTs 
Normal and FD (Q279E mutant) fibroblasts were cultured in the presence and 
absence of each DGJ-ArT and reference DGJ derivatives at varying concentrations. After 
96 hours, α-Gal A activity was determined (Figure 47a-b). 3 of the 4 designed DGJ-ArTs 
showed enhanced α-Gal A activity in the normal fibroblasts. Only DGJ-pMeSPhT did not 
give enhanced activity, with the other three designed DGJ-ArTs giving 1.2 to 1.5 fold 
increase (Figure 47a). In FD cells expressing mutant (Q279E) α-Gal A, all 4 designed 
DGJ-ArTs enhanced the α-Gal A activity. The effect of DGJ-pMeOPhT was the greatest, 
with a 3-fold activity increase over cell treated with DGJ and more than a 7-fold increase 







Figure 44 Crystal structure of α-Gal A in complex with DGJ-pFPhT 
(a) 2.55 Å resolution structure showing final 2Fo-Fc density at 1 σ in gray mesh for the DGJ-
pFPhT (yellow) and interacting residues of α-Gal A (blue). Green mesh is Fo-Fc density 
contoured at 3s (σ) after initial molecular replacement with apo α-Gal A from PDB ID 3GXN 
and first round of refinement, prior to modelling the chaperone. (b) Overlay of DGJ-bound 
structure (gray) and DGJ-pFPhT-bound structure (blue and yellow). (c) Hydrogen bonding 
network of α-Gal A and DGJ-pFPhT. Distances shown are average distances from two 
molecules in the asymmetric unit. (d) Hydrogen bonding network involving DGJ in the active 






   
            
Figure 45 Effects of DGJ-ArTs and derivatives on human normal fibroblast cells in vitro 
(a) Inhibition assay of DGJ-ArTs on α-Gal A in vitro. Enzyme activity was measured in cell 
lysate in the presence or absence of increasing concentrations of DGJ or DGJ derivative 
compounds. Each data point represents the mean ± the standard error of the mean (SEM) of 
three determinations, each done in triplicate. (b) Effects of 4 DGJ-ArTs and DGJ derivitives 




Table 19 IC50 values of DGJ derivative compounds against Gal A in vitro 
Activity was determined as described in Figure 45. 
 
pH 5 (µM) pH 7 (µM) 
Fold increase from 
pH 7 to pH 5 
DGJ-NphT 1.60 ± 0.092 0.37 ± 0.045 4.3 
DGJ-pMeOPhT 0.074 ± 0.0064 0.016 ± 0.0020 4.6 
DGJ-pMeSPhT 0.0083 ± 0.00051 0.0014 ± 0.00031 5.9 
DGJ-pFPhT 0.34 ± 0.047 0.043 ± 0.0062 7.9 
pFPhIM-DGJ 9.67 ± 0.88 2.81 ± 0.39 3.44 
DGJ-BnT 20.26 ± 2.43 4.41 ± 0.65 4.59 




Figure 46 Stabilization activity of DGJ and DGJ derivatives on α-Gal A in skin 
fibroblast cells.  
Cell lysate was incubated at pH 7.0 and 48°C for the indicated time and the α-Gal A activity 
was measured. Each point represents the mean of tripiclates obtained from three separate 





Cell toxicity of the pharmacological chaperones was measured by LDH assay and 
only DGJ-pMeSPhT was found to be cytotoxic (Figure 48a). DGJ-pMeOPhT was 
selected for immunofluoroescence study, using 30 µM concentrations. Treatment of 
Q279E FD fibroblasts with DGJ-pMeOPhT significantly reduced Gb3 accumulation, 
meaning the mutant enzyme is actively processing the substrate in the lysosome.  
6.3.4 The effect of DGJ-pMeOPhT on mutants of α-Gal A 
α-Gal A (WT and 17 missense mutants) were transiently transfected into COS7 
cells. DGJ-pMeOPhT significantly enhanced the activity of 15 out of 17 of the mutants, 
with the exception of E66Q and G373D (Figure 48b). The results for the other 3 DGJ-
ArTs were similar (data not shown).  
6.3.5 Autophagic proteins are upregulated in FD cells and restored by DGJ-
pMeOPhT and DGJ-FPhT 
SV-40 mediated transformed cell lines from normal and Q279E FD fibroblasts 
(FD-SV) were established for these experiments. DGJ-pMeOPhT and DGJ-pFPhT, 
increased α-Gal A activity in FD-SV, and had significant effect on activity over DGJ at 
30 µM concentration (Figure 49a).  
Autophagy-related proteins within were then analyzed using FD-SV cells. LC3-II, 
a specific autophagosome marker, was significantly increased in FD-SV cells over 
control cells, and a small increase in p62 was seen in FD-SV cells (Figure 49b). No 
difference in levels of beclin-1 and Bip was detected. FD-SV cells treated with 
chaperones DGJ-pMeOPhT and DGJ-pFPhT showed marked decrease in the levels of 








Figure 47 Gal-A activity is enhanced by DGJ-ArTs in normal and FD fibroblasts 
(a) Activity of 4 DGJ-ArTs, 2 DGJ derivatives, and DGJ on normal fibroblasts. (b) Activity of 
DGJ and derivatives on FD fibroblasts, measured in nmol/mg/hour. For a, b, and d, each bar 
represents the mean ± SEM of three experiments, each done in triplicate. (c) Cell toxicity 






Figure 48 Activity of DGJ-pMeOPhT on normal and FD fibroblasts, and COS7 cells 
expressing WT and mutant α-Gal A. 
(a) immunofluoroescencce of anti-Gb3 on normal and FD fibroblasts in the presence and 
absence of DGJ-pMeOPhT with quantification of Gb3 intensity. (b) Activity of DGJ-
pMeOPhT on COS7 cells with WT and mutant α-Gal expression. Each bar represents the 





6.3.6 Effects of proteostasis regulators on α-Gal A activity are additive 
Two proteostasis regulators, 4-PBA and celastrol, were added with DGJ-
pMeOPhT to test the added effect of mutant α-Gal A activity. Without the addition of 
DGJ-pMeOPhT, 4-PBA had a statistically significant effect on mutant α-Gal A activity. 
Notably, 0.1 mM 4-PBA in the presence of 20 µM DGJ-pMeOPhT had a very significant, 
additive effect on the activity. Celastrol had no effect on α-Gal A activity (Figure 50).  
 
Figure 49 Effects of DGJ-pMeOPhT and DGJ-pFPhT in the impairment of autophagy of 
FD fibroblasts 
(a) α-Gal A activity of transformed FD (SV-FD) fibroblasts in the presence and absence of 
DGJ and two DGJ-ArTs. Each bar represents the mean ± SEM of three experiments, each 
done in triplicate. *p < 0.05, statistically different from the activity of untreated samples. (b) 
Western blot analysis of proteins related to autophagy from normal and FD fibroblasts in FBS 
and in serum starvation medium. (c) Effect of DGJ-pMeOPhT and DGJ-pFPhT on levels of 








Currently, DGJ is in clinical trials for the treatment of Fabry disease, but DGJ has 
some drawbacks, mainly its hydophilicity which limits diffusion through cell membranes. 
Because of these issues, a new family of pharmacological chaperones for Fabry disease. 
DGJ-ArTs, were designed to have strong hydrogen bonding capabilities between Asp 231 
and the N’H proton. In this study, the 4 designed DGJ-ArTs were synthesized and tested 
in vitro.  
The molecular basis for DGJ-ArT binding to α-Gal A was elucidated by X-ray 
crystallography structure, and confirmed the hypothesis that the N’H proton of the 
arylthiourea would make a strong hydrogen bond donor for the catalytic residue, Asp 
231. Asp 170, while interacting with the endocyclic nitrogen in DGJ, interacts with OH4 
in DGJ-pFPhT. Other hydrogen bonding between α-Gal A and bound ligand DGJ-pFPhT, 
is very similar to that of DGJ (Figure 44), with the notable exception that hydrogen 
 
Figure 50 Effects of DGJ-pMeOPhT with proteostasis regulators on α-Gal A activity 
FD-SV cells were treated with 4-PBA and celastrol in the presence or absence of DGJ-
pMeOPhT. Each bar represents the mean ± SEM of three experiments, each done in triplicate. 
*p < 0.05, statistically different from the activity of α-Gal A in the absence of 4-PBA and 





bonding distances for the DGJ-pFPhT-bound structure are on average slightly longer than 
the distances for the DGJ-bound structure. The longer distances in the DGJ-pFPhT-bound 
structure could be because the fluoro substituent forms hydrogen bonding interactions 
with a residue from a neighboring molecule, specifically Arg 193. The DGJ-pFPhT-
bound structure was also solved at pH 4.5, likely changing the protonation state of some 
of the interacting residues and increasing bond length. Based on the crystallographic 
binding data, further substituents on the aryl ring can be explored to optimize the potency 
of the chaperone.  
An inhibition assay was done to determine IC50 values for the 4 DGJ-ArTs and 
the reference DGJ derivatives. DGJ-pMeSPhT had an IC50 value on the same order of 
magnitude as DGJ and all 4 DGJ-ArTs had significantly higher inhibitory potential than 
the reference DGJ derivatives. The difference in IC50 values confirms the superiority of 
DGJ-ArTs over the reference DGJ derivatives as active-site directed α-Gal A ligands. 
Notably, the designed DGJ-ArTs have a significant increase in inhibitory potency from 
pH 5.0 to pH 7.0. This is important because the pharmacological chaperone must bind 
tightly to the enzyme in the endoplasmic reticulum (neutral) to stabilize the enzyme, but 
dissociate in the lysosome (acidic) to resume normal function (Table 19).  
The activity assay with normal fibroblast cells revealed that little difference was 
seen between the designed DGJ-ArTs and the reference DGJ derivatives (Figure 47a), 
but a marked difference was observed in the FD fibroblast cells, which agrees with the 
starting hypothesis (Figure 47b). It is interesting that the optimal concentration for 
enhanced enzyme activity (30 µM) is about 3 times the IC50 value (Table 19 and Figure 




must be noted that the Km of α-Gal A for the natural substrate Gb3, and at sufficiently 
high substrate concentrations the competition for binding will favour the natural substrate 
over the pharmacological chaperone which will drive the reaction toward Gb3 processing 
(277). It is unknown if the enzyme can balance hydrolysis at substrate concentrations 
below Km, but the neutral nature of the DGJ-ArTs will likely be an advantage over the 
protonated inhibitor DGJ.  
The activity assay with 17 mutants of α-Gal A and DGJ-pMeOPhT (Figure 48b) 
is consistent with other studies of pharmacological chaperones where the enzyme being 
studied retains full or partial catalytic activity upon successful trafficking from the 
endoplasmic reticulum to the lysosome (269, 276). DGJ-pMeOPhT was successful in 
enhancing the activity of α-Gal A in 15 of the 17 mutants tested, showing its potential for 
treatment of Fabry disease.  
Since impairment of autophagy is a hallmark of cellular pathology in lysosomal 
storage disorders (278, 279), the levels of autophagy-related proteins, specifically LC3-II, 
p62, were tested (Figure 49). Levels of Bip, a protein related to ER stress, and beclin-1, a 
regulator of autophagy, were unchanged in FD-SV cells when exposed to starvation. This 
indicates that autophagy is impaired in the FD-SV cells, as expected. When FD-SV cells 
were treated with 2 DGJ-ArTs, levels of LC3-II and p62 both decreased, showing the 
great potential of the pharmacological chaperones for the treatment of Fabry disease.  
In this chapter, we discuss 4 novel DGJ-ArT pharmacological chaperones for the 
treatment of Fabry disease. The molecular basis for their binding has been studied by X-
ray crystallography and the compounds have been tested in normal and FD fibroblast 




them more suitable than the parent compound, DGJ. Based on our studies, DGJ-ArTs 
should be further explored for use as a treatment for Fabry disease, and design principles 





CHAPTER 7: PERSPECTIVES AND FUTURE 
DIRECTIONS ON THE USE OF EPITOPE-SPECIFIC 
CRYSTALLIZATION CHAPERONES 
7.1 PERSPECTIVES ON MEMBRANE PROTEIN CRYSTALLOGRAPHY 
Membrane protein crystallography requires a lot of trial and error, and there are 
no shortcuts. Nevertheless, as evidenced throughout this thesis, many lessons can be 
learned in the process leading to eventual success in membrane protein crystallization. 
The high-risk/high-payoff goal of my thesis project was to solve a high resolution co-
crystal structure of EE-tagged SPP in complex with the anti-EE Fab fragment, a goal that 
has yet to be attained.  Indeed, the paper that details the Nobel Prize-winning structure of 
β2AR in complex with its G protein ((105), see Chapter 1), has 20 authors (including key 
player in membrane protein crystallography in LCP, Martin Caffery), one of which 
(Brian Kobilka himself) was involved in the cloning of the first GPCR 25 years prior 
(280). Even after several GPCR structures had been solved and many of the techniques 
that were used for the β2AR-G protein structure had already been used for previous 
structures, the researchers still had to test ~50 ligands, test ~50 detergents, generate new 
antibody fragments, optimize the placement of the lysozyme, and screen hundreds of 
crystals before the structure was obtained.  
One important lesson from this thesis work is that it is not productive to set up 
crystallization trials of the same protein without making a major change. The changes I 
always made were in the crystallization trials: the sparse matrix screen used, temperature, 
protein concentration, method of protein complexation (adding the Fab/EE to the SPP-EE 




are very important, but when no crystals are obtained after several sparse matrix trays, 
larger changes are needed. Protein screening and engineering seem to be keys to solving 
membrane protein structures, which we did not realize in the early stages of this project. 
We knew that the TM6-TM7 loop of H. mar SPP was very long (and likely flexible). We 
knew that we could not successfully solubilise H. mar SPP in DDM. We knew that FC12 
was only once used successfully for every step of membrane protein isolation, 
purification, and crystallization, namely, the E. coli porin OmpF in 2010, a structure that 
had been previously solved in different detergents and was crystallized in FC12 as an 
accidental by-product (281). Perhaps we should have switched the target protein from H. 
mar SPP, which expressed extremely well, to M. mar SPP earlier, but this genome 
sequence was not available at the start of the project.  
At the Frontiers of Structural Biology Keystone Conference in 2014, I discussed 
membrane protein crystallography with many people. Dr. Bergeron sent me his protocol, 
which consisted of making a small clone library (4-8 variants, starting and ending at 
different points based on alignments and secondary structure predictions) of the protein 
of interest all in a vector that included a cleavable hexahistidine tag. Small scale 
expression trials were then done by growing and inducing 10 mL cultures and running 
samples on SDS-PAGE. This is a very simple way to test protein expression of several 
variants in parallel, similar to the expression trials we conducted with intimin, and likely 
how SPP screening started out before I joined the project. The next step I took (with all 
the M. mar SPP constructs) was to scale up the expression to 3 L of culture, isolate 
membrane, and purify, which was too slow.  The method of fusing GFP to the target 




investigators in assessing and optimizing protein expression (See Section 2.4), and a GFP 
fusion can be used with a fluorescence detector in line with size exclusion 
chromatography to assess the shape, intensity, and elution volume of the protein peak 
(see Section 2.2.7 and 2.3.4) without the need to purify the protein. This requires 
constructing GFP-fusions and acquiring an in-line fluorescence detector, though.  
Once expression and purification are optimized, a high (or medium) throughput 
way to determine protein stability in different conditions should be performed. The 
thermostability assay developed by the lab of Dr. Robert Stroud (159) is a useful tool if 
buried cysteine residues are present in the target protein. If no buried cysteines exist, SE-
HPLC and SDS-PAGE are alternatives (see Section 2.4). Our method of thermal 
unfolding using CD was effective in determining stabilizing detergents (see Figure 12), 
but time consuming; an alternative is needed.  
 
7.2 PERSPECTIVES ON THE USE OF EPITOPE-SPECIFIC CRYSTALLIZATION 
CHAPERONES FOR MEMBRANE PROTEINS 
From my thesis work, we now know that the insertion of the 6 amino acid EE 
epitope can cause a detrimental increase in flexibility of the loop where insertion 
occurred (see Figure 28). The flexibility of the linker region is likely the culprit for the 
difficulty in co-crystallization, as protein engineering efforts to decrease the loop 
flexibility with a shortened TM6-TM7 loop in M. mar SPP led to a promising co-crystal 
lead with complexed Fab/EE (see Section 4.3.4). Our method of using an epitope-specific 
antibody fragment as a chaperone is similar to the covalent addition of T4L to GPCRs 




both methods involve a short linker region (native loop residues) flanking a well folded 
protein. The covalent addition of T4L has been successful for numerous structures, likely 
because researchers tried many constructs prior to successful crystallization. In our 
attempt to develop a very general method that could be applied to any membrane protein, 
engineering of the protein to determine a suitable epitope insertion site was not attractive. 
Our method was supposed to be easier, less time-consuming, and less expensive than the 
generation of new crystallization chaperones for each target protein. It likely still will be, 
but several constructs of the membrane protein are probably going to need to be screened, 
paying careful attention to the loops within each protein target. Methods should be 
devised to scale up the process of evaluating chaperone binding to each potential 
membrane protein construct. In addition to optimization of Fab/EE:EE-tagged protein 
complexation, other epitopes (FLAG, for example) and fragment types (nanobody, for 
example) should be explored so that a toolbox of epitope-specific crystallization 
chaperones is generated, giving the researcher a choice for the optimal success.  
7.3 CONCLUSIONS 
In this thesis, I have presented the road taken to develop a stable, soluble, easily 
expressed and purified, epitope-specific antibody fragment as a general crystallization 
chaperone for membrane proteins. Though the long-term goal in obtaining a co-crystal 
structure of Fab/EE and SPP-EE was not realized, lessons that were learned on membrane 
proteins, detergents, antibody fragments, complexation, and complex crystallization are 
very important to the Lieberman lab and lay the foundation for the future success of 
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